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• We evaluated the evidence regarding the impact that interventions to reduce sedentary 
behaviour (sitting), alone or in combination with physical activity increases, may have on 
important indicators of cardiometabolic risk, when intervening for ≥ 7 days under free-living 
conditions.  
• Available evidence for different outcomes ranged from 6 to 25 controlled trials. On average, 
these interventions led to modest improvements in selected indicators of body anthropometry, 
glucose and lipid metabolism, and blood pressure regulation, with no adverse effects 
observed. 
• Our review noted potential improvements for future research: more high-quality studies and 
interventions > 12 months; more population diversity (based on ethnicity, age, and clinical 
factors); more sensitive biological indicators; and, more studies evaluating vascular function 
and inflammation. 
 




Context/Purpose: Observational and acute laboratory intervention research has shown excessive 
sedentary time is associated adversely with cardiometabolic biomarkers. This systematic review with 
meta-analyses synthesises results from free living interventions targeting reductions in sedentary 
behaviour alone or combined with increases in physical activity. 
Methods: Six electronic databases were searched up to August 2019 for sedentary behaviour 
interventions in adults lasting for ≥ 7 days publishing cardiometabolic biomarker outcomes covering 
body anthropometry, blood pressure, glucose and lipid metabolism, and inflammation (54 studies). 
The pooled effectiveness of intervention net of control on 15 biomarker outcomes was evaluated 
using random effects meta-analyses in the studies with control groups not providing other relevant 
interventions (33 studies; 6 to 25 interventions analysed).  
Results: Interventions between 2 weeks and < 6 months in non-clinical populations from North 
America, Europe and Australia comprised much of the evidence base. Pooled effects revealed small, 
significant (p < 0.05) beneficial effects on weight (≈ -0.6 kg), waist circumference (≈ -0.7 cm), 
percentage body fat (≈ -0.3 %), systolic blood pressure (≈ -1.1 mmHg), insulin (≈ -1.4 pM) and HDL 
cholesterol (≈ 0.04 mM). Pooled effects on the other biomarkers (p > 0.05) were also small, and 
beneficial in direction except for fat-free mass (≈ 0.0 kg). Heterogeneity ranged widely (I2 = 0.0 to 
72.9). 
Conclusions: Our review of interventions targeting sedentary behaviour reductions alone, or 
combined with increases in physical activity, found evidence of effectiveness for improving some 
cardiometabolic risk biomarkers to a small degree. There was insufficient evidence to evaluate 
inflammation or vascular function. Key limitations to the underlying evidence base include a paucity 
of high-quality studies, interventions lasting for ≥ 12 months, sensitive biomarkers and clinical study 
populations (e.g., type 2 diabetes).  
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Globally, cardiovascular diseases are the leading cause of death and a major cause of disability and 
lost productivity in adults [1, 2]. Estimates from 2017 also indicate that 451 million people are living 
with diabetes: a figure projected to rise to 693 million (≈10% of the population) by 2045 [3].  
The evidence tends to indicate that greater time spent in sedentary behaviour (i.e., sitting / reclining at 
<1.5 Metabolic Equivalents [MET]) [4] is adversely associated with the risk of cardiovascular disease, 
type 2 diabetes and some cancers [5, 6] and with levels of a range of cardiometabolic risk biomarkers 
[7, 8]. A less prolonged sedentary accumulation pattern (i.e., more regular breaks, shorter sedentary 
bouts) has also been associated with lower body mass index [8]. It has largely been acute laboratory 
interventions (<7 days) using structured protocols providing experimental evidence that reducing or 
breaking up sitting can have beneficial effects on certain cardiometabolic biomarkers [9-12]. For 
example, compared to uninterrupted sitting time, adding short bouts of light or moderate intensity 
activity every 20-30 minutes (generally over a period of one to five days), has led to improvements in 
resting blood pressure [13, 14], fasting and postprandial glucose [15, 16] and insulin [15, 17, 18], and 
some lipids [19].  
In recognition of the aforementioned evidence, several countries now, in addition to having guidelines 
concerning physical activity, include guidelines to reduce the quantity of sedentary behaviour and/or 
break it up [20-22]. A variety of intervention strategies have been trialled to reduce adults’ levels of 
sedentary behaviour, particularly in the workplace setting [23, 24]. Reviews indicate these 
interventions are often effective for reducing sedentary behaviour, especially workplace interventions 
incorporating environmental modification, ideally as part of a multicomponent intervention [23, 25-
27]. What is lacking, however, is an understanding of the nature and extent of health improvements 
that might be obtained when intervening to reduce sedentary behaviour over longer periods and under 
free-living conditions. A preliminary evaluation explored this topic (in workplace interventions only) 
but, having occurred prior to the emergence of several large trials of sedentary behaviour 
interventions, did not present any meta-analyses and could draw no firm conclusions [28]. 
We conducted this systematic review with meta-analyses aiming to synthesise the body of evidence 
that examined the effectiveness on biomarkers of cardiometabolic risk of ≥ 7 day interventions that 
target sedentary behaviour (alone or in combination with physical activity) in free-living conditions. 
We reviewed the evidence on body anthropometry, indicators of blood pressure and related 
haemodynamics, biomarkers relevant to the metabolism of blood glucose and lipids, and 
inflammatory biomarkers.  
 
2. METHODS 
This study followed the Preferred Reporting Items for Systematic reviews and Meta-analyses 
(PRISMA) [29] and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) [30] 
reporting guidelines. The systematic review protocol was prospectively registered on Prospero on 22 
June 2016 (CRD42016041742. Available from: 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42016041742).  
2.1 Search strategy and study selection 
Six electronic databases (Ovid Medline, Ovid Embase, EBM Reviews Cochrane Central, CINAHL, 
Scopus, Web of Science) were searched systematically from database inception to 27 August 2019 (7 
March 2017; 16 February 2018; and, 27 August 2019). A research librarian (LR) conducted an initial 
search for studies in Medline and Embase and used an analysis of text words and subject terms to 
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develop the search strategies. The final searches were then executed using the appropriate 
specifications of each database (LR; see Supplementary Material S1). Using reference management 
software (Endnote™, Clarivate Analytics, Philadelphia, USA), records were compiled, duplicates were 
removed, and two authors (NH and PD or RC and MG) performed title and abstract screening and 
reviewed each full-text article was reviewed against the inclusion criteria. Discrepancies were 
resolved in consultation with an independent third reviewer (EW). 
2.2 Inclusion and exclusion criteria 
Inclusion criteria, applied hierarchically, were: 1) reported intervening on sedentary behaviour for ≥ 7 
days; 2) human study; 3) participants all aged ≥ 18 years; 4) English language; 5) full-length 
publication; 6) reported as an outcome at least one biomarker of cardiometabolic health, specifically 
concerning body anthropometry, glucose metabolism, lipid metabolism, blood pressure and related 
haemodynamics, or inflammation (see Supplementary Material S1); and, 7) used an intervention study 
design (single-group pre-post intervention, parallel-group design, or crossover). To meet criterion 1), 
the intervention needed to target sedentary behaviour directly or indirectly with replacement of 
sedentary activity with an alternative (e.g., treadmill desks), increasing ‘whole-of-day’ activity (which 
includes sedentary) or increasing ‘light intensity’ activity (which is almost the inverse of sedentary) or 
similar. Studies that only mentioned intervening on ‘physical activity’ or exercise could increase these 
activities at the expense of either sedentary behaviour or light activity, and therefore did not meet 
criterion 1). Further inclusion criteria for the meta-analyses were: 1) a no-intervention comparison 
arm (usual care / conditions; attention control); and, 2) no other intervention that was likely to provide 
an appreciable impact on cardiometabolic biomarkers (e.g., diet). Physical activity interventions were 
permitted, since reducing sedentary time very likely increases some form of physical activity as a 
replacement. Achievement of successful sedentary behaviour change was not considered a 
requirement for inclusion in the meta-analyses (to avoid potentially overstating effectiveness). Meta-
analyses were conducted for each biomarker reported in at least five studies.   
2.3 Data extraction 
All data were extracted, checked and discrepancies resolved by the review team (NH, PD, RC, EW), 
using standardised rules created a priori. The rules used for regarding extraction, contacting authors 
for missing or questionable data are in Supplemental Material 2. Study quality was assessed using the 
Risk of Bias (RoB) 2.0 tool [31]. 
2.4 Statistical analysis 
Analyses were performed in STATA version 16 (StataCorp, Texas USA). Significance was set at p < 
0.05 (two-tailed). Pooled effects were estimated based on intervention effects (mean between-groups 
difference, in units) for the end-of-intervention endpoint extracted from each intervention, with the 
standard errors multiplied by √(𝑛 + 1)/2 whenever there were n > 1 eligible sedentary behaviour 
intervention arms [32]. Pooled effects were primarily estimated from random effects (Der Simonian 
Laird) meta-analysis models, with fixed effects results also reported, along with heterogeneity 
estimates (I2 and Cochrane’s Q test) in the forest plots. A range of sensitivity analyses were also 
performed. Since Begg’s test for publication bias can be underpowered, we also reported bias-
corrected estimates from Twedie and Duval’s trim and fill method. Leave-one-out sensitivity analyses 
were performed to consider how dependent conclusions were to any individual study. Meta-regression 
models, which explored possible sources of heterogeneity, are reported in the manuscript whenever 
heterogeneity was significant (p < 0.05) or substantial (I2 > 0.25), otherwise in supplementary 
material. Characteristics considered were: mean participant age, mean outcome biomarker levels at 
baseline, degree of intervention effectiveness for sedentary behaviour (intervention effect on overall 
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sedentary time in h/day), intervention duration (≤ 3 months / 3 to 6 months / > 6 months) and study 
quality (RoB scores). Unadjusted and age-adjusted models were reported.  
 
3. RESULTS 
3.1 Systematic Review 
3.1.1 Study inclusion 
Figure 1 shows the PRISMA flow diagram. In total, 23,976 articles were identified. Most were 
rejected at abstract screening, with 267 articles screened as full text. The criteria mostly excluded 
studies on the basis they were not ≥ 7 day sedentary behaviour interventions (181/218). Fifty-four 
studies (55 articles) were included in the systematic review [33-87].  
The population, design and intervention characteristics of the studies are reported in Supplementary 
Table S3 and aggregated in Table 1. Collectively, the 54 studies involved 6330 participants (48% 
women) with sample sizes usually < 100 (k=36) and occasionally >200 (k= 8), ranging between 12 
and 1113. Study populations were recruited from developed nations, mostly English-speaking (Table 
1) usually from North America (k=20, predominantly the USA), Europe (k=19), Australia (k=10) and 
occasionally from Asia (k=4) or Africa (k=1). From what little and inconsistent data was reported on 
ethnicity, plus the study locations, we infer that most study participants were likely Caucasian or 
‘White’ (variously defined) with a smaller number identifying as African American or African, 
Hispanic and Asian ethnicities. Study mean ages ranged from 23 years [74] to 71 years [51]. 
Typically, the studies recruited participants from the general population (k=26) or a population with a 
chronic disease risk factor (k=17) (generally overweight and/or obesity, occasionally in conjunction 
with another risk factor). Clinical conditions [36, 37, 39, 44, 48, 59, 60, 71, 72, 81, 84] were seldom 
targeted for recruitment; of these only some conditions were pertinent to cardiovascular health. Many 
studies (k=25) used screening to recruit participants at risk for high sedentary behaviour based on their 
job (e.g., office or desk-based work) and/or their reported behaviours, while 20 studies screened based 
on physical activity, and 11 studies screened on both behaviours.  
3.1.2 Interventions  
The 54 studies delivered 56 sedentary behaviour interventions, mostly in the workplace (k=27) or 
community (k=18) settings, with healthcare (k=9), domestic (k=1) and educational settings (k=1) 
being less common (Table 1, details in Supplementary Table S3). Workplace interventions were about 
half multicomponent (k=13) and half single component (k=14), while interventions in the remaining 
non-workplace settings were mostly multicomponent (k=21, 72%). Workplace interventions almost 
all used environmental modification (k=26), commonly used counselling/education (k=13), sometimes 
used device self-monitoring (k=5), device-based social comparison (k=3), prompting via devices or 
SMS (k=6), and structured activity sessions (k=2). By contrast, non-workplace interventions almost 
always used some form of counselling/education (k=29), commonly used device self-monitoring 
(k=18) and occasionally used environmental modification (k=8), prompting (k=6), structured activity 
(k=4) and financial incentives (k=1). The extent of education or counselling was also highly variable, 
ranging from brief advice to theoretically grounded behavioural counselling.   
The interventions varied in how they considered sedentary behaviour. Diverse behaviours were 
promoted as replacements for sedentary behaviour: primarily standing, walking or other stepping, but 
also sometimes pedalling, ‘incidental’ exercise (likely predominantly ‘light’ activities), activities of 
moderate or greater intensity, and sometimes resistance exercise (Supplementary Table S3). Sedentary 
behaviour targets seldom were domain specific, referenced accumulation patterns or set quantitative 
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guidelines on sedentary time (Table 1). Primary outcomes included sedentary behaviour in 23 studies, 
biomarkers in 11, and included neither in 20, instead being unstated (k=6), focused on feasibility 
(k=5), or involving physical activity with or without other outcomes (k=9).  
3.1.3 Evaluation of biomarker indicators of cardiovascular health 
The biomarkers selected for review are shown in Table 2. Biomarker outcomes nearly always 
included indicators of body anthropometry (k=52 studies), and often included indicators of blood 
pressure (k=37), lipid metabolism (k=33), and glucose metabolism (k=31). Four studies reported on C-
reactive protein [72, 73, 75, 87]. Other inflammatory markers such as TNF-α or IL-6 were not found 
among the reported outcomes.  
Of the anthropometric indicators, the most commonly reported were weight (k=45) or BMI (k=39), 
followed by waist circumference (k=37). These were almost always collected objectively by staff. 
Body composition outcomes were collected mostly using multifrequency bioimpedance analysis 
(BIA; k=12) or reference-grade standards: dual X-ray absorptiometry (DXA; k=5) or body air 
displacement plethysmography (BADP; k=3). Occasionally, other methods were used (k=4). Studies 
typically reported on body fat (k=25) (most commonly as percentage of body weight), and 
occasionally fat-free, lean or muscle mass (k=13). Thus, fewer studies were able to assess changes to 
specific tissues (e.g., fat, lean tissue) or anatomical sites (e.g. truncal fat, measured in 4 studies).  
Blood pressure was generally assessed with resting blood pressure (k=37), which was typically 
reported separately as systolic (k=37) and/or diastolic blood pressure (k=36) and as mean arterial 
pressure in two studies [57, 82] (Table 2). Usually, staff measured blood pressure, with participants 
reporting values from home monitors in one study [46]. Ambulatory blood pressure was not reported. 
Detailed biomarkers of vascular health (e.g., endothelial dysfunction, arterial stiffness) were seldom 
collected. One study reported on flow mediated dilatation, carotid artery intima media thickness, 
aortic augmentation index, and sub endocardial variability [53]. Resting heart rate was collected in 
three studies [62, 69, 73].  
Of the glucose metabolism indicators (Table 2), most (k=27) reported on fasting glucose, with only 13 
reporting fasting insulin, and 7 reporting composite indicators of beta-cell function or insulin 
resistance (i.e., measures from homeostatic model assessment, HOMA or HOMA-2). Seventeen 
studies reported on overall glucose control (HbA1c expressed in various forms), while four studies 
reported effects on postprandial glucose and/or insulin [54, 58, 71, 83] and none reported on c-
peptide. While venous blood draws were the norm for collecting fasting values (k=20 studies), lower 
quality fingerstick capillary measures were occasionally used (k=7). None of the studies reported 
outcomes from continuous glucose monitoring.  
The most commonly reported lipid markers were: triglycerides (k=32); total cholesterol (k=29); High-
Density Lipoprotein (HDL) cholesterol (k=28); and, Low-Density Lipoprotein (LDL) cholesterol 
(k=24) (Table 2). These markers are reported widely in the context of cardiovascular risk. Studies 
occasionally reported VLDL cholesterol [69], non-LDL cholesterol [40], or cholesterol ratios [40, 42, 
43, 60, 70]. Three studies reported on apolipoproteins (APOA1, APOB and their ratio [38, 70, 73]) 
and one reported on the diameter of various types of cholesterol [38]. None of the studies mentioned 
performing detailed profiling of lipid classes or subclasses.  
3.1.4 Study designs 
Very few studies (k=5) used a single-group pre-post study design (Table 1) [46, 51, 63, 69, 78]; most 
used two or more groups (k=49). Usually the additional group (or groups) facilitated testing 
effectiveness against a no-intervention or attention control comparison arm (k=44, with 39 
randomised) or occasionally only allowed for comparison of alternate interventions (k=5, with 5 
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randomised) [34, 44, 50, 67, 84]. Most studies (k=42) intervened for six months or less (shortest = two 
weeks) while few (k=10) intervened for 12 months or longer [43, 44, 46, 59, 60, 63, 72, 73, 76, 87] 
(longest = 36 months). Only nine studies referred to evaluation of maintenance of effects following 
withdrawal of intervention or intervention contact.   
  
3.2 Meta-Analysis 
3.2.1 Study inclusion 
Of the 44 controlled intervention studies, 33 studies (34 interventions) were eligible for the meta-
analyses (11 studies had provided diet intervention). For the 15 biomarkers that met the inclusion 
criteria (Table 2), the number of studies providing data and able to be included ranged from 6 for fat 
mass to 25 for body weight and blood pressure, and these studies collectively represented anywhere 
between 724 and 2076 participants.  
3.2.2 Risk of bias  
Risk of bias overall is reported in Supplementary Table S6. To simplify reporting, criteria scored for 
groups of outcomes with similar concerns underlying their bias risk (e.g., missing data, measurement): 
anthropometric and blood pressure outcomes, glucose metabolism outcomes, and lipid metabolism 
outcomes. Overall risk of bias was high (≥ 1 criteria was ‘high’ risk) in 10 studies (30%), unclear (i.e., 
0 ‘high’ risk and ≥ 1 ‘unclear’ risk) in 17 (52%) studies and ‘low’ (i.e., all ‘low’ risk) in 6 studies 
(18%). The most common contributor to a ‘high’ risk of bias rating related to the randomisation 
process (k=6, 18%) [58, 64, 68, 76, 79, 87], (i.e., use of non-random methods). Four studies were also 
rated as ‘high’ risk of bias due to deviations from intended interventions (data not analysed according 
to intention to treat principles [40, 58, 74, 79]), and missing outcome data [76, 79, 83, 87]. An unclear 
risk level was typically assigned based on inadequate reporting of randomisation (k=12), concerns 
with missing outcome data (k=11), and/or bias in measurement of the outcome (k=9). Low risk was 
still permitted with lack of blinding, given the context (behavioural intervention) in which allocation 
is impossible to conceal from participants and is generally known to staff, and in which outcomes are 
collected objectively. 
3.2.3 Effectiveness of sedentary behaviour interventions for biomarker outcomes 
Effects on biomarkers were evaluated in the context of interventions that had displayed overall 
sedentary time improvements net of control that were mostly moderate (k=12, 30 to < 60 min/day), 
otherwise strong (k=9, ≥ 60 min/day) or small (15 to < 30 min/day, k=8), or occasionally almost zero 
(k=3, -15 to < 15 min/day). Effects ranged from +11.3 to -132 min/day (see Supplementary Table S4). 
Table 4 shows the pooled effects on biomarkers for the main analyses and sensitivity analyses. Begg’s 
tests were all p ≥ 0.05 (Supplementary Table S7).   
Body weight and body composition 
Consistent with the studies’ selection criteria, prior to intervention, participants had a weighted mean 
(± Pooled SD) BMI of 25.4 ± 3.2 kg/m2, with study means ranging from 22.1 kg/m2 in a workplace 
intervention with no weight screening criteria [68] to 35.9 kg/m2 in a treadmill intervention for 
overweight/obese office workers [56]. Baseline anthropometric values are summarised in Table 3 
(detail in Supplementary Table S4). Pooled effects showed that the sedentary behaviour interventions 
tended to provide small improvements (net of control) in body anthropometry outcomes (Table 4). 
Significant pooled effects in favour of intervention were seen regarding body weight (-0.56 kg, 95% 
CI: -0.94, -0.17), waist circumference (-0.72 cm, 95% CI: -1.21, -0.22), body fat percentage (-0.26 %, 
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95% CI: -0.50, -0.02), with a tendency towards reduced fat mass (-0.33 kg, 95% CI: -0.74, 0.08) and 
no large or significant effect on fat-free mass (0.00 kg, 95% CI: -0.52, 0.53). Effects on BMI were in a 
similar direction to those for body weight, but not statistically significant (-0.07 kg/m2, 95% CI: -0.16, 
0.03). Forest plots for body weight and body composition are shown in Supplementary Figures 1 to 6. 
Small-study effects did not lead to overstated findings, as the original findings were no more 
favourable than the trimmed and filled results. Also, no single study seemed to overly influence the 
conclusions, as improvements observed were always still present to some degree in the leave-one-out 
sensitivity analyses.  
Body weight and body fat percentage showed little evidence of heterogeneity (I2 < 25%; p ≥ 0.05) 
with slightly more substantial (but non-significant) heterogeneity seen for fat mass and significant 
heterogeneity seen for waist circumference and fat-free mass. The heterogeneity in effects on fat-free 
mass was completely attenuated (I2 =0.0, p = 0.790) by omitting a single study [45]. Omission of this 
same study partially attenuated heterogeneity in effects on waist circumference (I2 =19.9%, p=0.217). 
Further exploration of the heterogeneity via meta-regression (Table 5) did not show any significant 
predictors of effects on waist circumference. The largest effects and the smallest residual 
heterogeneity were seen for risk of bias scores (residual I2 =22.6%, p = 0.192), with effects stronger 
by just over 1 cm in studies with high versus low risk of bias. Meta-regression results for the 
outcomes not displaying substantial or significant heterogeneity are shown in Supplementary Table 
S8. 
Blood pressure 
Prior to intervention, participants had a weighted mean (± Pooled SD) blood pressure of 110.0 ± 10.5 
mmHg systolic and 78.4 ± 7.1 mmHg diastolic, indicating typically healthy levels, though with some 
studies attracting samples with average systolic blood pressure as high as 140 mmHg or higher [55, 
70] (Table 3 and Supplementary Table S4). Pooled effects showed a small significant reduction in 
systolic blood pressure (-1.05 mmHg, 95% CI: -2.08, -0.02) and a smaller non-significant reduction in 
diastolic blood pressure (-0.69 mmHg, 95% CI: -1.69, 0.32; Table 4). Forest plots are shown in 
Supplementary Figures 7 and 8. Corrections for small-study effects had no effect on the results and 
pooled effects consistently reflected tendencies towards reduced blood pressure in the leave-one-out 
sensitivity analyses. Heterogeneity was minimal for systolic blood pressure (I2 = 8.6, p = 0.341) but 
extensive for diastolic blood pressure (I2 = 52.6, p=0.001), and not explained by any single study. 
None of the variables in the meta-regressions (Table 5) had significant associations with diastolic 
blood pressure or reduced the heterogeneity appreciably (residual I2 > 50).  
Glucose metabolism 
Prior to intervention, fasting glucose averaged 4.7 ± 1.0 mM, indicating levels consistent with healthy 
metabolism or pre-diabetes rather than diabetes. However, the studies covered a diverse spectrum 
from 4.1 mM in a study of healthy adults [83] to 7.6 mM in a study of type 2 diabetes patients aged 
40–80 years [72]. Baseline insulin and HbA1c levels averaged 51.5 ± 44.1 pM and 4.4 ± 0.6% were 
also quite variable across studies (Table 3 and Supplementary Table S5). Pooled effects pointed to 
small benefits to glucose metabolism, which were statistically significant only for fasting insulin (-
1.42 pM, 95% CI: -2.82, -0.02) and small non-significant tendencies towards lower fasting glucose (-
0.03 mM, 95% CI: -0.11, 0.05) and HbA1c (-0.10 %, 95% CI: -0.22, 0.03). Forest plots are shown in 
Supplementary Figures 9 to 11. Small-study effects may have overstated effects on insulin and 
HbA1c. 
Glucose, insulin, and HbA1c all showed substantial heterogeneity (I2 = 45.5 for glucose to I2 = 72.9 
for insulin; p < 0.05), which remained present in all the leave-one-out sensitivity analyses, except for 
glucose, where removing a single workplace study [49] that had failed to elicit changes in sedentary 
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behaviour markedly attenuated the heterogeneity (I2 = 28.4, p = 0.126). Insulin outcomes were 
significantly beneficially associated with lower baseline levels, shorter intervention duration, and 
higher risk of bias, with limited residual heterogeneity after accounting for risk of bias (I2 = 11.9, p = 
0.338); however only the association with baseline level remained significant accounting for age 
(residual I2 = 0.0, p = 0.641). Higher participant age significantly predicted enhanced HbA1c 
outcomes, and led to lower heterogeneity (residual I2 = 49.5, p = 0.054) while in age-adjusted models, 
effects were significantly beneficially associated with higher BMI, longer intervention duration and 
lower risk of bias, and a borderline association with higher baseline levels. The model with age and 
BMI had no residual heterogeneity (I2 = 0.0, p = 0.454). 
Lipid metabolism 
Prior to intervention, baseline levels averaged 4.3 ± 0.6 mM total cholesterol, 1.2 ± 0.4 mM HDL, 2.5 
± 0.8 mM LDL and 1.1 ± 0.5 mM triglycerides, with comparatively limited variation across studies 
relative to other biomarkers (Table 3 and Supplementary Table S5). Small significant improvements 
in response to sedentary behaviour interventions were seen in HDL cholesterol (0.04 mM, 95% CI: 
0.02, 0.07) alongside a small, non-significant improvement in total cholesterol (-0.06 mM, 95% CI: -
0.16, 0.04) and very small, non-significant effects on LDL cholesterol (-0.02 mM, 95% CI: -0.07, 
0.04), and triglycerides (-0.02 mM, 95% CI: -0.09, 0.04). Forest plots for cholesterol and triglycerides 
are shown in Supplementary Figures 12 to 15. Small study effects if anything limited the effects seen 
for lipid metabolism, with trimmed-and-filled estimates all either larger or virtually unchanged, and 
with a significant effect on total cholesterol emerging (-0.10 mM, 95% CI: -0.20, -0.00). 
There was limited heterogeneity in outcomes concerning HDL and LDL cholesterol (I2 < 25, p ≥ 0.05) 
and more substantial and significant heterogeneity in total cholesterol (I2 = 54.1, p=0.001) and 
triglycerides (I2 = 49.0, p=0.005). Removing one study [36] markedly lowered the total cholesterol 
heterogeneity (I2 = 21.1, p = 0.183) while the same was not the case for triglycerides. Meta-
regressions (Table 5) showed significantly greater reductions in total cholesterol were seen with 
higher age, and higher risk of bias, with limited residual heterogeneity left after accounting for age (I2 
= 17.1, p=0.233) while in age-adjusted models, significant predictors of greater reductions were 
shorter study duration and higher risk of bias. It appears multiple factors may have contributed to the 
heterogeneity in triglyceride outcomes. None of the variables significantly predicted effects on 
triglycerides and residual heterogeneity remained high in all models (Residual I2 =45.1–53.6). In age-
adjusted models, less effectiveness in improving sedentary behaviour outcomes significantly predicted 
greater reductions in triglycerides (-0.13 mM, 95% CI: -0.21, -0.05), with very limited heterogeneity 
left when considering both these factors simultaneously (I2 = 0.0, p=0.507), which also involved 
excluding one study [74] due to missing data.  
 
4. DISCUSSION 
Several reviews have reported on sedentary behaviour interventions in relation to sedentary behaviour 
outcomes [23, 26, 27] and found them to be effective, to varying degrees. These reviews indicated 
success seemed to vary depending on factors including the focus on sedentary behaviour (alone versus 
in combination with other lifestyle behaviours) and the type of intervention (with multicomponent 
workplace interventions being particularly successful). The current systematic review with meta-
analyses considered these interventions in the context of their effect on biomarkers of cardiometabolic 
health, finding a small body of evidence. In total, 54 studies were identified, with 33 eligible for the 
meta-analyses, and with 6 to 25 controlled interventions ultimately included in meta-analyses 




Broadly, the meta-analyses provided some support for small improvements in selected indicators of 
body anthropometry, blood pressure, glucose metabolism and lipid metabolism with intervention, 
with none of the outcomes tending to worsen with intervention. Specifically, significant 
improvements were seen in body weight, waist circumference, percentage body fat, systolic blood 
pressure, insulin and HDL cholesterol. For some outcomes, findings varied widely from study to 
study, while for others they were quite consistent, with heterogeneity ranging widely (I2 = 0.0 to 
72.9). It may be the case that some types of interventions are effective (and others ineffective), and/or 
the interventions may be effective in some populations but not others. The sensitivity analyses and 
meta-regressions provided some insight into potential factors underlying some of the heterogeneous 
results. Sometimes a single study deviating from the general pattern appeared to be the issue, while 
other key factors (different for each outcome) tended to be due to participant age and BMI, study 
duration and risk of bias. There were very few studies with each characteristic; consequently, the 
confidence intervals around effects were quite wide, and findings should not be taken to indicate non-
significant predictors in the meta-regressions were unimportant. The low number of studies was also 
the reason stratified analyses were not performed to inform the effectiveness of specific types of 
interventions, for specific populations (e.g., men, women, older adults, and those with clinical 
conditions such as type 2 diabetes). Some potential success factors not able to be explored were 
ethnicity (poorly reported), sex, behaviour settings and dose-response. Prior findings have sometimes 
suggested the biological responses to sedentary time may vary depending on the setting or context in 
which it occurs [88, 89], by ethnicity [90-92], by sex [18, 91, 93, 94], and by the activity replacing 
sedentary time [95-98]. 
The systematic review showed some key considerations for interpreting the effectiveness findings. 
The sedentary behaviour interventions performed were highly varied in terms of their setting, use of 
behaviour change components, and the degree of emphasis on sedentary behaviour; thus, the 
heterogeneous outcomes were not highly surprising. Also, some caution should be exerted in 
extrapolating findings to groups with limited or no representation in the evidence base. Evidence has 
mostly been collected from studies of Caucasian or ‘White’ populations (variously defined) of 
working age, often with overweight/obese BMI or waist circumference, with very limited 
representation of those with clinical conditions pertinent to cardiovascular health, such as type 2 
diabetes. The short duration of most interventions may have influenced the degree of effectiveness 
observed in the meta-analyses; there was a paucity of studies intervening ≥ 12 months and including 
maintenance evaluations from which to consider sustainability or determine what may happen in the 
longer term. Previously, it has been reported that biomarker results have been more promising at 12 
months compared to 3 months, despite sitting reduction being greatest at 3 months [43].  
To overcome the limitations of the current evidence the next logical step would be individual patient 
data meta-analysis, with interventions collecting ‘dose’ data regarding sedentary behaviour and the 
activities that may replace it in the most harmonisable way possible, even if this is only possible in a 
subsample of participants. Ideally, the measurement should allow both calculation of some total dose 
(e.g., in MET-hours), as well as partial out time spent sedentary and in various alternative behaviours, 
delineated by intensity, posture and accumulation method (e.g., sedentary/sitting, standing, light 
movement, moderate movement, vigorous movement, and bouted versus non-bouted forms of the 
relevant behaviours). Such an approach may help to determine the populations for which each 
intervention may be effective, as well as ascertain which specific behaviours (if any) may achieve the 
greatest biomarker improvements.  
Other key features identified within the current evidence base are the type, reporting (or lack thereof) 
and specificity/sensitivity of biomarkers outcomes collected. For example, most of the biomarkers 
collected (e.g., blood glucose, insulin, triglycerides and blood pressure) are subject to homeostatic 
regulation but were only measured in fasted or resting states. It is important to also evaluate how 
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some sensitive biomarkers (without these limitations) that have fairly consistently responded 
beneficially in acute laboratory interventions lasting < 7 days [9, 11, 12, 99] respond over longer 
intervention timeframes. Specifically, postprandial glucose, insulin, triglycerides and ambulatory 
blood pressure should be measured. Other understudied outcomes that are potentially useful to 
measure are: detailed markers of vascular haemodynamics and structure (e.g., cardiovascular and 
cerebrovascular blood flow, flow-mediated dilatation and arterial stiffness) [99, 100]; C-peptide; 
continuous glucose monitoring; postprandial lipids; lipid subclasses [101, 102]; site-specific tissue 
samples (e.g., muscle, adipose tissue); and, additional intermediate biomarkers (such as those related 
to systemic metabolic/oxidative stress and inflammation)[9, 100]. These outcomes could be collected 
in all participants or in subsamples as they represent opportunities to detect changes that might 
otherwise be missed and improve our understanding of shared risk factors and potential mechanistic 
pathways. 
There were some caveats regarding the overall quality of the evidence. Trimmed and filled results 
mostly suggested publication bias did not affect findings, but the insulin finding may be overstated 
and some of the lipid findings understated. Inferences were sometimes made from a very small 
number of studies (especially regarding biomarkers of glucose and lipid metabolism), which is 
especially concerning with the findings varying so much between studies. The paucity of ‘low’ risk of 
bias studies is a limitation, though importantly most studies had an ‘unclear’ rather than a ‘high’ risk 
of bias and the meta-regressions did not usually show high risk of bias equated to the most promising 
results (if anything, findings showed the opposite).  
 
5. CONCLUSIONS 
This systematic review with meta-analyses synthesised the body of work concerning the effectiveness 
of sedentary behaviour interventions on biomarkers of cardiometabolic risk, specifically: body 
anthropometry; blood pressure and related haemodynamics; glucose metabolism; lipid metabolism; 
and, inflammation. Consistent with evidence from prior observational research and acute laboratory-
based experiments (< 7 days) linking sedentary behaviour with cardiometabolic health [8, 11, 12], the 
evidence from ≥7 day interventions in free-living conditions showed small improvements in some 
cardiometabolic biomarkers. These biomarker improvements definitively occurred in response to 
interventions targeting sedentary behaviour (alone or alongside physical activity), but how they 
occurred in response to sedentary reductions and increases in various forms of physical activity 
remains unknown. Our review indicated that studies in clinical populations, ethnicities other than 
Caucasian or ‘White’ in predominantly Western countries, and evaluation of biomarkers of 
inflammation and postprandial metabolism are key areas for future research. 
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a exclusion criteria were applied in the following order: 1) not sitting intervention ≥ 1 week, 2) not a human 
study, 3) not English language, 4) not full-length publication, 5) not reporting ≥ 1 biomarker, 6) not randomised, 
quasi-randomised or pre-post trial, 7) not adults ≥ 18 years. 
b Two articles were identified for one study (Balducci 2017, Balducci 2019) 
c k=32 for anthropometry measures; k=25 for blood pressure measures; k=22 for glucose measures; k=24 lipid 





Table 1 Summary of the study population, design and intervention characteristics of adult sedentary 
behaviour interventions ≥ 7 days with biomarker outcomes 
Characteristic  Count 
a  
Detail 
Population / study characteristics (54 studies)   
Sample size 
  
Median n/study 57 Lowest = 12, Highest = 1113 






North America 20 USA 16, CA 4 
Europe 19 UK 5, DK 4, SE 3, ES 2, NL 1, DK & GL 1, FI 1, IT 1, 
UK & NL & NO & PT 1 
Australia 10  
Asia 4 TW 2, CN 1, JP 1 




>50% Caucasian / ‘white’ 18   
<50% Caucasian / ‘white’ 2   





Clinical condition 11 T2D 4, Cancer 2, Rheumatoid Arthritis 2, Obstructive 
Sleep Apnoea 1, Intellectual Disability 1, Coronary 
Artery Disease 1 
Clinical risk factors only 17 Adiposity 14, Chronic disease risk (+ adiposity) 3 
Healthy / general  26   
Screening 
  
Sedentary job / behaviour 25 11 also screened for PA, 14 did not 





Randomised Controlled Trial 39 8 cluster / 31 individually randomised 
34 parallel group / 3 crossover / 1 other b  
Non-randomised Controlled Trial 5 1 cluster / 4 individually allocated  
5 parallel group / 0 crossover 
Multi-arm (no controls) 5 1 cluster randomised / 4 individually randomised  




Includes sedentary 22   
Includes biomarker(s) 10   
Includes both 1   
Includes neither 21 PA 8 / PA & diet 1, Unstated 6, Feasibility, 5 Fitness 




3 months or less 28   
>3-6 months 16   




Workplace 27   
Community 18   
Other 11 Hospital 5, Primary care 4, Domestic 1, Education 1 
N components 
  
Multicomponent 34 Workplace 13, Community/Other 21 








Counselling/education 41 Workplace 13, Community/Other 28 
Environmental modification 34 Workplace 26, Community/Other 8 
Prompting 12 Workplace 6, Community/Other 6 
Structured 'activity' 5 Workplace 2, Community/Other 4 
Device self-monitoring 23 Workplace 5, Community/Other 18 
Device social comparison 7 Workplace 3, Community/Other 4 
Financial incentives 2 Workplace 1, Community/Other 1 
Sedentary 
targets / 
messaging c  
Domain specific message 29   
Accumulation 21   
Quantitative volume target 14   
BMI = Body Mass Index; WC = Waist Circumference; PA = Physical activity 
a count out of 54 studies or 56 interventions as indicated in the table unless other statistic is mentioned (e.g., 
median).  
b almost a randomised controlled trial (parallel groups) except re-enrolled some controls into the intervention 
upon completion.  
c Not mutually exclusive (interventions can have multiple components, multiple messages) 
20 
 
Table 2 Biomarkers reported as outcomes in 54 studies of adult sedentary behaviour interventions ≥ 7 
days 
 
Outcomes Studies   Detail Quality factors 
Body Anthropometry 52     
Body weight a 45 45 weight a, 39 body mass index a Objective b / self-report: 44 / 1  
Waist circumference a 37 37 circumference a, 2 waist-hip ratio Objective b / self-report: 36 / 1 
Other body measurements 9 7 hip circumference, 1 neck circumference, 2 
sagittal abdominal diameter 




Skinfold(s): 2  
Unreported: 1 
-Total fat  25 20 percentage of body weight a, 11 mass a 
-Total fat-free or lean  13 12 percentage of body weight, 1 mass a, 
-Other 5 fat mass or % (4 truncal, 1 arm, 1 leg, 1 android %, 
1 gynoid %); fat-free mass or % (1 arm, 1 leg); 1 
skeletal muscle mass; 1 visceral fat area 
Blood Pressure (BP) 
Regulation 
37     
Resting BP a 37 37 systolic a, 36 diastolic a 2 mean arterial BP Objective b / self-report: 36 / 1 
Ambulatory BP 0 - - 
Heart rate 5 3 resting, 2 non-resting Objective b / self-report: 5 / 0 
Detailed vascular health 
measures 
3 1 flow mediated dilation, 1 carotid intima media 
thickness, 1 aortic augmentation index, 1 
subendocardial variability, 1 pulse wave velocity 
Objective b / self-report: 3 / 0 
Glucose Metabolism 31     
Fasting glucose a 27   Venous / Capillary: 20 / 7 
Fasting insulin a 13   
HOMA/HOMA-2  7 6 HOMA-IR, 2 HOMA-%B, 1 HOMA2-%B, 1 
HOMA2-%S 
Postprandial glucose / 
insulin 
4 4 postprandial glucose, 1 postprandial insulin, 1 
Insulin AUC, 1 Glucose AUC, 1 C-ISI 
Venous / Capillary: 4 / 0 
Duration: all 2 h test 
C-peptide 0   - 
HbA1c a 17 15 HbA1c, 2 'estimated average glucose' reported 
as HbA1c 
Venous / Capillary: 15 / 2 
Lipid Metabolism 33     
Cholesterol levels or ratios 33 29 total a, 28 HDL a, 24 LDL a, 1 VLDL, 1 non-
LDL, 5 Total/HDL, 2 LDL/HDL  
Venous / Capillary: 25 / 8 
 
Fasted / Insufficient / Non-
fasted state: 25 / 1 / 7 
Triglycerides a 32  
Other  3 1 Cholesterol diameter; 1 Lipoprotein Lipase; 3 
Apolipoproteins (APO): 3 APO-A1, 3 APO-B, 2 
APO-A1/APO-B 
Inflammation 4     
C-reactive protein (CRP) 4 2 CRP; 2 high-sensitivity CRP Venous / Capillary: 4 / 0  
Fasted / Insufficient / Non-
fasted state: 4 / 0 / 0 
Other: TNF-α, IL-6 0   - 
    
 
HOMA = Homeostatic Model Assessment; HOMA-2 = Revised Homeostatic Model Assessment; HDL = high-
density lipoprotein; LDL= low-density lipoprotein; TNF-α = tumour necrosis factor alpha; IL-6= interleukin 6. 
BIA = multifrequency bioimpedance analysis; DXA = dual X-ray absorptiometry; BIS = bioelectrical 
impedance spectroscopy; BADP = body air displacement plethysmography; AUC = area under the curve; C-ISI 
= composite insulin sensitivity index.  
a Outcome included in the meta-analyses: was reported in > 5 of the 33 studies eligible for the effectiveness 
meta-analyses (had control arm, no additional relevant intervention provided apart from active behaviours) 
b Measured objectively by research staff 
Note. Data were extracted from the earlier paper related to this study (Balducci 2017) when it was not reported 




Table 3 Average biomarker characteristics prior to intervention in controlled trials of 34 adult sedentary behaviour interventions ≥7 days with biomarker 
outcomes 
 
 k n Weighted mean 
± pooled SD 
Study means 
(min – max) 
Study with lowest mean Study with highest mean 
Weight, kg 29 2456 71.3 ± 10.6 62.2 – 99.6 Alkhajah et al. (2012) MacEwen et al. (2017) 
Body mass index, kg/m2 34 3186 25.4 ± 3.2 22.1 – 35.9 Alkhajah et al. (2012) Schuna et al. (2014) 
Waist circumference, cm 21 2630 83.9 ± 7.7 74.4 – 111.4 Butler et al. (2018) MacEwen et al. (2017) 
Body fat, % 18 2050 28.1 ± 5.4 24.5 – 45.5 Dunning et al. (2018) Kozey-Keadle et al. (2014) 
Fat mass, kg 7 753 25.3 ± 7.7 18.4 – 32.3 Alkhajah et al. (2012) Kallings et al. (2009) 
Fat-free mass, kg 8 1252 40.0 ± 6.7 44.1 – 56.5 Alkhajah et al. (2012) Balducci et al. (2019) 
Systolic BP, mmHg 25 2461 110.0 ± 10.5 109 – 142 Dunning et al. (2018) Maxwell-Smith et al. (2018) 
Diastolic BP, mmHg 25 2457 68.4 ± 6.5 69 – 86 Peterman et al. (2019) MacEwen et al. (2017); Maxwell-Smith et. al (2018) 
Glucose, mM 19 1975 4.7 ± 1.0 4.1 – 7.6 Peterman et al. (2019) Balducci et al. (2019) 
Insulin, pM 11 1495 51.5 ± 44.1 37.1 – 133.0 Dunning et al. (2018) Kozey-Keadle et al. (2014) 
HbA1c, % 11 1308 4.4 ± 0.6 4.9 – 7.4 Kallings et al. (2009) Balducci et al. (2019) 
Total cholesterol, mM 24 2292 4.3 ± 0.6 4.0 – 5.5 Peterman et al. (2019) Kallings et al. (2009) 
HDL cholesterol, mM 22 2232 1.2 ± 0.4 1.1 – 1.8 Peterman et al. (2019) Pesola et al. (2017) 
LDL cholesterol, mM 21 2142 2.5 ± 0.8 2.5 – 3.3 Peterman et al. (2019) Kallings et al. (2009) 
Triglycerides, mM 23 2202 1.1 ± 0.5 0.9 – 1.9 Alkhajah et al. (2012) Kozey-Keadle et al. (2014) 
k= number of interventions, n = number of participants 





Table 4 Pooled intervention effects on biomarkers: controlled trials of 35 adult sedentary behaviour interventions ≥7 days  
n 
Outcome Main findings Publication-bias 
corrected 
Leave-one-out sensitivity analysis 
k n All studies Most benefit Least benefit 
I2, p Pooled effect (95% 
CI) 
p Pooled (95% CI) Pooled effect (95% 
CI) 
Pooled effect (95% 
CI) 
Weight, kg 25 1839 23.6%, p=0.142 -0.56 (-0.94, -0.17) 0.005 n/a -0.63 (-1.03, -0.23) a -0.47 (-0.75, -0.18) b 
Body Mass Index, kg/m2 24 1843 0.0%, p=0.804 -0.07 (-0.16, 0.03) 0.167 -0.08 (-0.17, 0.02) -0.10 (-0.20, 0.01) c -0.04 (-0.14, 0.06) d 
Waist circumference, cm 19 2076 45.8%, p=0.016 -0.72 (-1.21, -0.22) 0.004 -1.00 (-1.51, -0.49) -0.95 (-1.38, -0.51)# e -0.61 (-1.20, -0.01) # f 
Body fat, % 16 1618 5.5%, p=0.390 -0.26 (-0.50, -0.02) 0.034 -0.37 (-0.65, -0.10) -0.37 (-0.61, -0.12) c -0.17 (-0.43, 0.09) e 
Fat mass, kg 6 724 26.6%, p=0.235 -0.33 (-0.74, 0.08) 0.116 n/a -0.42 (-0.73, -0.10) g -0.23 (-0.63, 0.16) h 
Fat-free mass, kg 7 1011 72.7%, p=0.001 0.00 (-0.52, 0.53) 0.992 0.48 (-0.02, 0.98) 0.12 (-0.40, 0.65) c -0.25 (-0.57, 0.06) # e 
Blood pressure, mmHg         
Systolic 25 1932 8.6%, p=0.341 -1.05 (-2.08, -0.02) 0.045 n/a -1.42 (-2.38, -0.45) c -0.75 (-1.81, 0.31) i 
Diastolic 25 1932 52.6%, p=0.001 -0.69 (-1.69, 0.32) 0.180 n/a -0.92 (-1.86, 0.02) j -0.36 (-1.28, 0.56) k 
Glucose, mM 19 1518 45.5%, p=0.017 -0.03 (-0.11, 0.05) 0.526 -0.04 (-0.13, 0.05) -0.05 (-0.11, 0.02)# l -0.01 (-0.11, 0.09) i 
Insulin, pM 10 1102 64.0%, p=0.003 -1.42 (-2.82, -0.02) 0.047 -1.03 (-2.48, 0.42) -4.13 (-7.48, -0.78) m -0.45 (-1.60, 0.69) #a 
HbA1c, % 9 892 72.9%, p=0.000 -0.10 (-0.22, 0.03) 0.129 -0.03 (-0.16, 0.09) -0.14 (-0.29, 0.01) n -0.05 (-0.17, 0.07) h 
Cholesterol, mM         
Total 23 1798 54.1%, p=0.001 -0.06 (-0.16, 0.04) 0.213 -0.10 (-0.20, -0.00) -0.08 (-0.18, 0.02) l -0.03 (-0.11, 0.05) #o 
High Density Lipoprotein 22 1760 22.5%, p=0.168 0.04 (0.02, 0.07) <0.001 0.05 (0.02, 0.07) 0.05 (0.03, 0.07) d 0.03 (0.01, 0.06) i 
Low Density Lipoprotein 20 1660 0.0%, p=0.690 -0.02 (-0.07, 0.04) 0.562 -0.01 (-0.07, 0.05) -0.03 (-0.09, 0.03) l -0.00 (-0.06, 0.06) p 
Triglycerides, mM 23 1742 49.0%, p=0.005 -0.02 (-0.09, 0.04) 0.496 -0.06 (-0.13, 0.01) -0.04 (-0.10, 0.03) g -0.01 (-0.07, 0.06) h 
 
k, n = number of interventions, number of individuals (sum of n analysed in each included study) 
Boldface indicates pooled effect is p < 0.05 *Heterogeneity p < 0.05 # Heterogeneity no longer p < 0.05 in leave-one-out sensitivity analysis 
a Omitted Healy et al. (2017)  b Omitted Ashe et al. (2015) c Omitted Maylor et al. (2018) d Omitted Pesola et al. (2017)  e Omitted Danquah et al. (2017) f Omitted Puig-
Ribera et al. (2015) g Omitted Healy et al. (2013) h Omitted Kallings et al. (2017) i No Butler et al. (2018) j Omitted Mantzari et al. (2018) k Omitted Lin et al. (2017) l 





Table 5 Associations of study characteristics with intervention effects on cardiometabolic biomarkers (meta-regression) 
 
  Unadjusted Age adjusted 
  k, n b (95% CI) p I2, p n, N b (95% CI) p I2, p 
Waist circumference, cm 19, 2076   45.8%, p=0.016 19, 2076   45.8%, p=0.016 
Mean baseline age, per 10 y 18, 2050 -0.50 (-1.18, 0.17) 0.144 51.6%, p = 0.007   - - - 
Mean baseline BMI, kg/m2 19, 2076 -0.04 (-0.25, 0.16) 0.672 48.6%, p = 0.011 18, 2050 -0.01 (-0.24, 0.22) 0.910 54.5%, p = 0.005 
Mean baseline level 19, 2076 0.01 (-0.08, 0.09) 0.856 44.9%, p = 0.021 18, 2050 0.07 (-0.03, 0.18) 0.182 45.9%, p = 0.023 
Sedentary effectiveness, h/day c 19, 2076 -0.62 (-1.42, 0.18) 0.127 38.7%, p = 0.048 18, 2050 -1.05 (-1.96, -0.14) 0.023 40.3%, p = 0.049 
Duration (vs ≤3 months) 19, 2076  0.896 51.8%, p = 0.007 18, 2050  0.307 57.7%, p = 0.003 
3–6 months   0.15 (-1.08, 1.37) 0.816     0.92 (-0.69, 2.52) 0.262   
>6 months   -0.36 (-2.28, 1.57) 0.717     -0.25 (-2.28, 1.78) 0.809   
Risk of bias (vs High risk) 19, 2076  0.098 22.6%, p = 0.192 18, 2050  0.109 25.4%, p = 0.174 
Some concerns   -0.70 (-2.50, 1.09) 0.441     -0.52 (-2.39, 1.34) 0.582   
Low risk   -1.47 (-3.10, 0.16) 0.077     -1.36 (-3.03, 0.31) 0.110   
Fat-free mass, kg 7, 1011   72.7%, p=0.001 7, 1011    72.7%, p=0.001 
Mean baseline age, per 10 y 7, 1011 0.14 (-0.60, 0.88) 0.714 74.5%, p = 0.001   - - - 
Mean baseline BMI, kg/m2 7, 1011 0.07 (-0.18, 0.32) 0.575 76.8%, p <0.001 7, 1011 0.07 (-0.24, 0.38) 0.660 79.6%, p = <0.001 
Mean baseline level 7, 1011 0.04 (-0.10, 0.18) 0.540 75.0%, p = 0.001 7, 1011 0.06 (-0.16, 0.27) 0.618 79.4%, p = <0.001 
Sedentary effectiveness, h/day c 7, 1011 0.23 (-0.98, 1.44) 0.711 77.1%, p <0.001 7, 1011 0.21 (-1.02, 1.44) 0.738 79.4%, p = <0.001 
Duration (> 6vs ≤3 months) d 7, 1011 0.06 (-1.23, 1.36) 0.922 77.1%, p <0.001 7, 1011 -0.14 (-1.86, 1.58) 0.875 77.6%, p = 0.001 
Risk of bias (vs High risk) 7, 1011  0.490 69.9%, p = 0.010 7, 1011  0.619 74.5%, p = 0.008 
Some concerns   0.72 (-0.53, 1.98) 0.258     1.23 (-0.73, 3.20) 0.219   
Low risk   0.12 (-1.10, 1.34) 0.847     0.37 (-1.07, 1.81) 0.615   
Glucose, mM 19, 1518   45.5%, p=0.017 19, 1518   45.5%, p=0.017 
Mean baseline age, per 10 y 19, 1518 -0.01 (-0.08, 0.07) 0.891 47.9%, p = 0.012   - - - 
Mean baseline BMI, kg/m2 19, 1518 0.01 (-0.01, 0.03) 0.391 46.0%, p = 0.017 19, 1518 0.01 (-0.01, 0.04) 0.330 48.8%, p = 0.012 
Mean baseline level 18, 1497 -0.01 (-0.23, 0.20) 0.908 45.8%, p = 0.021 18, 1497 0.03 (-0.23, 0.29) 0.819 46.0%, p = 0.023 
Sedentary effectiveness, h/day c 18, 1497 -0.02 (-0.21, 0.16) 0.804 45.6%, p = 0.021 18, 1497 -0.05 (-0.25, 0.15) 0.632 46.0%, p = 0.023 
24 
 
Duration (vs ≤3 months) 19, 1518  0.611 51.5%, p = 0.007 19, 1518  0.732 54.0%, p = 0.005 
3–6 months   -0.00 (-0.19, 0.19) 0.980     0.04 (-0.24, 0.32) 0.769   
>6 months   -0.12 (-0.37, 0.13) 0.345     -0.14 (-0.43, 0.15) 0.355   
Risk of bias (vs High risk) 19, 1518  0.424 48.3%, p = 0.014 19, 1518  0.543 49.7%, p = 0.013 
Some concerns   0.18 (-0.13, 0.48) 0.256     0.21 (-0.12, 0.54) 0.212   
Low risk   0.12 (-0.09, 0.33) 0.267     0.17 (-0.09, 0.42) 0.202   
Insulin, pM 10, 1102   64.0%, p=0.003 10, 1102   64.0%, p=0.003 
Mean baseline age, per 10 y 10, 1102 0.76 (-2.63, 4.15) 0.660 68.0%, p = 0.002   - - - 
Mean baseline BMI, kg/m2 10, 1102 0.20 (-1.09, 1.48) 0.764 67.8%, p = 0.002 10, 1102 0.02 (-1.60, 1.65) 0.980 68.8%, p = 0.002 
Mean baseline level 10, 1102 0.15 (0.03, 0.27) 0.018 61.1%, p = 0.008 10, 1102 0.21 (0.12, 0.31) <0.001 0.0%, p = 0.641 
Sedentary effectiveness, h/day c 10, 1102 1.65 (-6.15, 9.45) 0.678 66.5%, p = 0.002 10, 1102 3.51 (-6.34, 13.35) 0.485 45.4%, p = 0.077 
Duration (vs ≤3 months) 10, 1102  0.014 50.8%, p = 0.047 10, 1102  0.268 57.8%, p = 0.027 
3–6 months   2.14 (-7.20, 11.48) 0.654     1.87 (-8.64, 12.38) 0.728   
>6 months   7.87 (-0.21, 15.95) 0.056     6.84 (-2.33, 16.01) 0.144   
Risk of bias (vs High risk) 10, 1102  <0.001 11.9%, p = 0.338 10, 1102  0.211 22.8%, p = 0.255 
Some concerns   -0.24 (-1.42, 0.94) 0.692     -3.10 (-11.81, 5.62) 0.486   
Low risk   -4.64 (-6.95, -2.32) <0.001     -5.60 (-11.33, 0.14) 0.056   
HbA1c, % 9, 892    72.9%, p=0.000 9, 892   72.9%, p=0.000 
Mean baseline age, per 10 y 9, 892 -0.10 (-0.18, -0.02) 0.011 49.5%, p = 0.054   - - - 
Mean baseline BMI, kg/m2 9, 892 -0.01 (-0.05, 0.03) 0.599 76.3%, p<0.001 9, 892 -0.03 (-0.05, -0.01) 0.004 0.0%, p = 0.454 
Mean baseline level 9, 892 -0.15 (-0.34, 0.04) 0.127 76.3%, p <0.001 9, 892 -0.16 (-0.32, 0.00) 0.055 49.1%, p = 0.067 
Sedentary effectiveness, h/day c 9, 892 0.08 (-0.10, 0.26) 0.379 69.5%, p = 0.002 9, 892 -0.02 (-0.20, 0.17) 0.862 56.4%, p = 0.032 
Duration (vs ≤3 months) 9, 892  0.994 78.0%, p <0.001 9, 892  0.002 24.7%, p = 0.249 
3–6 months   -0.02 (-0.35, 0.32) 0.919     0.04 (-0.14, 0.23) 0.641   
>6 months   -0.02 (-0.38, 0.35) 0.932     -0.24 (-0.50, 0.02) 0.069   
Risk of bias (vs High risk) 9, 892  0.090 75.4%, p <0.001 9, 892  0.037 59.4%, p = 0.031 
Some concerns   0.30 (-0.25, 0.85) 0.287     0.28 (-0.23, 0.79) 0.286   
Low risk   0.50 (-0.02, 1.02) 0.058     0.40 (-0.09, 0.89) 0.113   
25 
 
Diastolic Blood Pressure, 
mmHg 25, 1932    52.6%, p=0.001 25, 1932   52.6%, p=0.001 
Mean baseline age, per 10 y 25, 1932 -0.38 (-1.30, 0.54) 0.421 54.4%, p <0.001   - - - 
Mean baseline BMI, kg/m2 24, 1903 -0.01 (-0.32, 0.30) 0.946 53.2%, p = 0.001 24, 1903 0.03 (-0.31, 0.36) 0.885 55.2%, p = <0.001 
Mean baseline level 24, 1911 -0.16 (-0.44, 0.12) 0.250 52.0%, p = 0.002 24, 1911 -0.11 (-0.42, 0.20) 0.492 52.5%, p = 0.002 
Sedentary effectiveness, h/day c 23, 1882 -1.07 (-2.83, 0.69) 0.232 52.9%, p = 0.002 23, 1882 -1.69 (-3.40, 0.02) 0.053 43.2%, p = 0.019 
Duration (vs ≤3 months) 25, 1932  0.655 56.2%, p <0.001 25, 1932  0.712 57.9%, p = <0.001 
3–6 months   0.22 (-2.50, 2.94) 0.874     0.40 (-2.64, 3.43) 0.798  
>6 months   -1.20 (-3.97, 1.57) 0.397     -1.14 (-4.19, 1.92) 0.465   
Risk of bias (vs High risk) 25, 1932  0.699 55.1%, p <0.001 25, 1932  0.629 57.1%, p = <0.001 
Some concerns   1.20 (-2.05, 4.45) 0.468     1.82 (-1.90, 5.53) 0.338   
Low risk   1.03 (-1.58, 3.64) 0.439     1.35 (-1.56, 4.25) 0.363   
Total Cholesterol, mM 23, 1798   54.1%, p=0.001 23, 1798   54.1%, p=0.001 
Mean baseline age, per 10 y 23, 1798 -0.14 (-0.22, -0.07) <0.001 17.1%, p = 0.233   - - - 
Mean baseline BMI, kg/m2 23, 1798 0.01 (-0.02, 0.04) 0.664 54.6%, p = 0.001 23, 1798 0.01 (-0.01, 0.03) 0.398 17.4%, p = 0.233 
Mean baseline level 23, 1798 -0.24 (-0.50, 0.02) 0.066 45.7%, p = 0.011 23, 1798 -0.05 (-0.30, 0.21) 0.713 20.6%, p = 0.195 
Sedentary effectiveness, h/day c 23, 1798 0.08 (-0.04, 0.20) 0.206 40.3%, p = 0.027 23, 1798 0.01 (-0.10, 0.12) 0.812 19.5%, p = 0.208 
Duration (vs ≤3 months) 23, 1798  0.573 54.6%, p = 0.001 23, 1798  0.003 20.4%, p = 0.202 
3–6 months   0.07 (-0.17, 0.31) 0.577     0.06 (-0.12, 0.24) 0.493   
>6 months   0.13 (-0.12, 0.39) 0.306     0.11 (-0.08, 0.30) 0.259   
Risk of bias (vs High risk) 23, 1798  0.044 47.2%, p = 0.009 23, 1798  <0.001 13.7%, p = 0.284 
Some concerns   -0.34 (-0.65, -0.04) 0.028     -0.21 (-0.48, 0.06) 0.134   
Low risk   -0.11 (-0.39, 0.16) 0.419     -0.05 (-0.29, 0.19) 0.689   
Triglycerides, mM 23, 1742   49.0%, p=0.005 23, 1742   49.0%, p=0.005 
Mean baseline age, per 10 y 23, 1742 -0.05 (-0.11, 0.02) 0.149 51.3%, p = 0.003   - - - 
Mean baseline BMI, kg/m2 23, 1742 0.00 (-0.02, 0.02) 0.962 50.3%, p = 0.004 23, 1742 0.01 (-0.02, 0.03) 0.667 52.4%, p = 0.003 
Mean baseline level 22, 1721 -0.20 (-0.63, 0.22) 0.350 45.1%, p = 0.014 22, 1721 -0.13 (-0.53, 0.26) 0.508 31.7%, p = 0.087 
Sedentary effectiveness, h/day c 22, 1721 -0.06 (-0.17, 0.05) 0.279 45.9%, p = 0.012 22, 1721 -0.13 (-0.21, -0.05) 0.001 0.0%, p = 0.507 
Duration (vs ≤3 months) 23, 1742  0.645 53.4%, p = 0.002 23, 1742  0.447 55.7%, p = 0.001 
26 
 
3–6 months   -0.07 (-0.24, 0.10) 0.402     -0.05 (-0.24, 0.14) 0.639   
>6 months   -0.06 (-0.25, 0.13) 0.516     -0.07 (-0.28, 0.13) 0.481   
Risk of bias (vs High risk) 23, 1742  0.396 53.6%, p = 0.002 23, 1742  0.485 55.7%, p = 0.001 
Some concerns   -0.13 (-0.33, 0.07) 0.218     -0.07 (-0.34, 0.19) 0.587   
Low risk   -0.10 (-0.28, 0.07) 0.245     -0.06 (-0.28, 0.16) 0.573   
 
Table presents unstandardized regression coefficient (b) and 95% confidence interval (CI) and p value from meta-regression of controlled trials of adult sedentary behaviour 
interventions ≥7 days. Italics indicates overall p value (omnibus test). 
a k = total number of interventions included and n = total number of individuals analysed in the included interventions, in the meta-regressions or main meta-analysis 
(boldface) b Residual heterogeneity (I2 and p from Cochrane’s Q test) with overall heterogeneity in the main meta-analysis shown in boldface c Estimated effectiveness of 
intervention on overall sedentary time (net of control) d No studies in the 3–6 month duration category.   
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Fig. 1 PRISMA diagram of the literature search results. 
190x190mm (300 x 300 DPI) 
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Supplemental Material S1 Searches performed for Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, 
Ovid MEDLINE(R)
# Searches Resultsa
1 Sedentary Lifestyle/ or Television/ or Computers/ or Video Games/ 0
2 (sitting or sedentary).tw. 5374
3 ((reclining or lying) adj4 (time* or bout* or posture* or position*1)).tw. 264
4
((screen or screens or screenbased or TV or television* or computer* or device* or smartphone* or phone* 
or tablet* or ipad* or DVD or video*) adj4 (time* or hours or watch* or view*)).tw.
4377
5 ((computer* or internet*) adj ("use" or "useage" or "usage" or behavio?r*)).tw. 543
6 ((reading or gaming) adj3 time*).tw. 276
7
((videogam* or video game* or computer game* or electronic game*) adj5 (time* or bout* or hours or 
watch* or view*)).tw.
103
8 Automobile Driving/ 0
9 ((car or cars or automobile* or driving or commute* or commuting) adj3 time*).tw. 254
10 (physical* adj3 inactiv*).tw. 1158
11 ((inactive or inactivity) adj3 (time* or bout* or hours)).tw. 102
12 (low adj2 energy expenditure*).tw. 34
13 (low adj2 physical activity*).tw. 357
14 or/1-13 11977
15 ((cardiovascular or cardiometabolic or cardio-metabolic) adj2 risk*).tw. 10453
16 (metaboli* or dysmetaboli*).tw. 92550
17 body mass index/ or exp overweight/ or waist circumference/ or waist-hip ratio/ 0
18
Body Weight/ or Weight Loss/ or Weight Gain/ or exp Adipose Tissue/ or Adiposity/ or body composition/ 
or body fat distribution/
0
19 exp Blood Pressure/ or exp Proinsulin/ or exp Adipokines/ or exp Somatomedins/ or exp Lipids/ 0
20 Hemoglobin A, Glycosylated/ or Biological Markers/ 0
21 C-Reactive Protein/ or Tumor Necrosis Factor-alpha/ or Interleukin-6/ or exp Fibrinogen/ 0
22 (glycosuria* or hyperglyc?emi* or hyperinsulin* or hypertensi* or prehypertensi*).tw. 37777
23 (glucose or blood sugar* or glyco* or glyca* or glyce*).tw. 79568
24 (overweight or over-weight or obesity or obese or BMI or body mass index or body mass indicator*).tw. 49646
25 (waist circumference* or waist-hip ratio* or adiposity or adipose or fatty tissue*).tw. 13449
26 (weight adj1 (gain* or increase* or loss* or decrease* or reduc* or lose* or losing or fluctuat*)).tw. 16489
27 (body adj (fat or composition or weight)).tw. 20018
28 (blood pressure or diastolic or systolic).tw. 27762
29 (proinsulin* or insulin* or c-peptide* or adiponectin* or leptin* or resistin* or somatomedin*).tw. 28561
30
(lipid* or triglycerid* or triacylglycerol* or lipoprotein* or apolipoprotein* or apoprotein* or 
chylomicron* or diglycerid* or diacylglycerol*).tw.
49109
31
(dyslipid* or dyslipoprotein* or hyperlipid* or hyperlip?emi* or lip?emi* or lipid?emi* or 
hypercholesterol* or hyperlipoprotein* or hypertryglycerid*).tw.
8511
32 (HDL or LDL or VLDL or cholesterol*).tw. 19137
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33 (biologic* marker* or biomarker* or immun* marker* or biochemical marker*).tw. 34917
34 (c-reactive or crp or fibrin* or hscrp or homocystein*).tw. 14516
35 (il6 or il-6 or interleukin-6 or tumo?r necrosis factor alpha or tnf-a or tnf-alpha).tw. 19760
36 ((glycate* or glycosylate*) adj2 (hemoglobin* or haemoglobin*)).tw. 2598
37 (hb a1* or hba1*).tw. 4575
38 (HOMA or homeosta* model assessment*).tw. 2421
39 or/15-38 334401
40 movement/ or locomotion/ or walking/ or motor activity/ or exercise/ or resistance training/ 0
41 physical exertion/ or physical fitness/ 0
42 accelerometry/ or actigraphy/ 0
43




((activit* or movement* or motion or fitness) adj2 (monitor* or assess* or measure* or track* or 
sensor*)).tw.
10370
45 (physical* adj2 (fit* or activ* or train*)).tw. 14689
46 (ambulation* or ambulatory activit* or walk or walking).tw. 12556
47 ((light or moderate or intensity) adj2 activit*).tw. 2040
48 (step or steps or stepping).tw. 76852
49 (sit-stand* or stand-step* or standing).tw. 10846
50




(Actiheart or Actical or Movemonitor or Tractivity or Yamax or Sensewear or Misfit or IDEEA or 
DirectLife or SmartShoe).tw.
700
52 (3dNX or ADXL322 or DynaPort MiniMod or EGAS device or GENEA or Minimod or RT3 device).tw. 9
53 (Digi-Walker or Caltrac or RT3 triaxial or Tracmor2 or Lifecorder or Walk4Life).tw. 13
54




56 (randomized controlled trial or controlled clinical trial).pt. 307
57 (random* or quasirandom* or trial or placebo).tw. or clinical trial*.sh. 156307
58 cross-over studies/ or (cross-over or crossover).tw. 9949
59 or/56-58 162180
60 14 and 39 and 55 and 59 402
61 exp animals/ not humans.sh. 1
62 60 not 61 402
63 limit 62 to english language 399
aResults are displayed for the initial search (March 03 2017). Identical searches were performed, ultimately covering 
research up to February 16 2018.
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Supplemental Material S2 Rules used for extracting data for the meta-analyses 
Consideration Rule a
Quality control One enters, another checks, discrepancies are discussed and resolved. 
Intervention 
selection
The sedentary-behaviour only intervention in a factorial design. All 
sedentary behaviour interventions within a study for multiple differing 
interventions. 
NOTE: The only meta-analysed multi-arm studies were Taylor et al. 20xx 
(both included) and Kozey-Keadle et al. 2014 (only one intervention 
included).
Endpoint selection End of intervention. If unavailable, use interim results or results averaged 
across several follow-up endpoints (only if the authors indicate no 
difference between these follow-up endpoints.)
NOTE: all estimates extracted were end of intervention except Balducci 
2017 reported some outcomes not in Balducci 2019.
Statistical 
conversions
and .𝑆𝐸 =  (Upper – Lower Limit)/(2 × 1.96) 𝑆𝐸 =  𝑆𝐷/ 𝑛
Unit conversions* 1 kg = 0.453592 pounds
1 inch = 2.54 cm
1 mM = 18 mg/dl (glucose)
1 mM =  38.67 mg/dl (cholesterol)
1 mM = 88.57 mg/dl (triglycerides)
1 μU/mL = 6 pmol/L insulin
NGSP HbA1c = (0.09148*IFCC HbA1c) + 2.152
eAG  = 1.59 * NGSP HbA1c - 2.59
Percentage of baseline values: * baseline values / 100 
Intervention effect 
extraction (minimum 
required data = 
intervention effect 
and its SE)
To maximise the amount of available data while retaining sufficient 
similarity for pooling. In order of preference extract:
Intervention effects (between-group differences in change, in units)
1. As reported
2. Calculated from each group’s reported mean changes
3. Calculated from each group’s reported means at baseline and 
follow-up (i.e., follow-up mean – baseline mean). 
4. By requesting sufficient data to apply #1 or #2 from the authors
Standard Error (SE) of intervention effect above
1. From reported SE or 95% Confidence Intervals (CI)
2. By performing an independent samples t-test from within-group 
data, using standard deviations (SD) or SE of change
3. By requesting sufficient data to apply #1 or #2 from the authors
4. By performing an independent samples t-test of using (SD) within-
group data, using standard deviations (SD) or SE at end of 
intervention. 
NOTE: Data were requested from 11 authors and 5 provided data while 6 
did not respond or could not acquire the data, leading to the use of 
estimates from end-of-intervention SE for 4 studies and data being 
unreportable from 2 studies.
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Outcomes in review 
but not in paper
This is a high-burden request. Contact authors and request only when a 
very similar outcomes was reported (e.g., fat mass / percentage body fat, 
weight / BMI, cholesterol ratios / values) and request only from authors on 
the research team. NOTE: This occurred for Alkahjah et al 2019, Healy 
2013 and Healy 2017. 
Errors suspected In order of preference
1. attempt to verify mathematically and resolve mathematically from 
other data reported
2. contact authors
NOTE: Authors contacted were Ashe et al (2015) (large weight 
discrepancy; verified outcomes were correct); Biddle et al. (2015) 
(identical values for >1 outcome; provided new data); Mantzari et al 
(2019) (95% CI not logical; provided new data); Thomsen et al. 2016 and 
Thomsen et al. 2017 (impossible units mM HbA1c; responded was eAG 
mM, with the following conversion formula listed in unit conversions)
a The same general procedures were applied in extracting intervention effects on sedentary behaviour 
outcomes, and baseline values of age and the biomarker outcomes, except that authors were not 
contacted to obtain further baseline data, only intervention effects.
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Table S3: Study and intervention characteristics
Study Details Intervention details
Study (Year);














RCT 6 months r I: C/ED (community)
-C/ED (4x FtF sessions, each 6








4) All sitting bouts
≤ 30 min








nRCT 3 months r I: Environmental (workplace)
-EM (individual sit-stand
workstation)
-EM-ED (1x Ftf  demonstration [≈2
min] + written instructions on use)
C: Usual conditions






x̅= 60.6 years (25-70)
x̅= 29.9 kg/m2 (all)
Ethnicity not reported
Type 2 diabetes
RCT 3 months 9M I: Multicomponent (primary
healthcare)
- C/ED (10 min FtF information
provision diet/PA; 1 h FtF workshop
on use of app)
- Structured exercise (5x FtF
moderate intensity 4 km walks
(1/week for 5 weeks), nurse-
delivered)
- Device self-monitoring (app;
removed at 3 months)
C: Usual care: (+ 10 min FtF
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RCT 6 months r I: Multicomponent (community)
-C/ED (9x FtF sessions:  ≈1h group
& ≈10-15 min individual PA
prescription delivered by exercise
physiologist; + ≈1h group
brainstorming delivered by project
staff)
- Device self-monitoring (Fitbit)
C: Attention control (Non-activity
health information)













RCT 36 months r I: Multicomponent (primary care)
-C/ED (1x FtF session, 30 min,
diabetologist-delivered)
-Structured exercise (8x FtF sessions
30 min aerobic, 30 min resistance, 15













Ball  et al.
(2017); Australia
46F, 36M




PP 4 months r I: Multicomponent (community)
- C/ED (1 x Tel session, research
staff delivered, 20 min)
-SMS goals, prompts (≈16 at 1/week)











x̅= 51.4 years (40-67)
x̅= ? kg/m2 (25-40)
Ethnicity not reported





RCT 13 months r I1: Multicomponent (workplace)
- EM: Treadmill workstation
- C/ED:  (1x FtF nurse-delivered
health consultation including SB, diet
and PA), 4x emails (sedentary
behaviour & treadmill use)
C: Usual care (+1x FtF nurse-
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At risk for type 2
diabetes or obese***
RCT 12 months r I: Multicomponent (community)
- C/ED (1x FtF group structured
education workshop, 3h +1x Tel call,
[duration unknown])
-Device self-monitoring (Gruve)
C: Attention control (information
leaflet on diabetes, PA and sedentary)
Reduce sedentary
behaviour




x̅= 22.7 years (≥18)
x̅= 23.0 kg/m2 (all)
71.4% C/W / 23.8%
Black / 4.8% Hispanic
University students ≥5
h/week in a specific
building
RCT-x 3 weeks r I: Environmental (university)

















RCT 12 weeks r I: Multicomponent (workplace)
-C/ED  (website messaging:
motivational including prompting, 1
message /day + 3 emails/week, ≈120
total)
-EM (individual portable pedal
machine with PC software)
-EM-ED (researcher-assisted setup &
instruction on use + website prompts
for usage)
- Device self-monitoring & social
comparison (pedometer challenge)
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c-RCT 3 months r I: Multicomponent (workplace)
-EM (general walking routes + shared
high tables)
-C/ED (FtF 1x 15 min lecture &
workshop [duration unknown])
-Online/SMS support (weekly emails
or 2/week SMS, ≈12-24 total)
C: Usual conditions










x̅= 27.5 years (18-45)




RCT 10 weeks r I: Environmental (workplace)
SMS prompts / reminders: (every 30




















RCT 18 months 6M I: C/ED (community)
-C/ED only (4x weekly + 5x
fortnighly + 12x monthly calls, 20-30
min)
C: Usual care
1) Sit less 2) Break














x̅= 24.8 kg/m2 (all)
Ethnicity not reported
Workers (office)
c-RCT 12 months r I: Multicomponent (workplace)
-EM (individual sit-stand
workstation)
- C/ED (1x FtF group structued
education session + ergonomic
education on workstation)
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Gill et al. (2019);
Canada
93F, 25M
x̅= 57.7 years (18-85)*
x̅≈ 31.4  kg/m2 (>25*)
98% C/W




MVPA, < 8 fruit & veg
serves/day, type 2
diabetes)





-C/ED (Online & app supported
health coaching with exercise
prescription & SB advice (4x FtF
sessions [≈30-40 min] at 0, 2, 4, 6
months), telephone coaching, app-
based virtual coaching)
-Device, app & web-based self-
monitoring, networking/support &
social comparison















RCT 8 weeks r I: Environmental (workplace)
-EM (individual sit-stand
workstation)
-EM-ED (Manufatcturer brief FtF














c-RT 12 months r I1: Multicomponent (community)
-C/ED (9-12x initial +  6x
maintenance FtF sessions with
participant & carer, 40-60 min,
delivered by dietician & health
professional)
-Device self-monitoring (pedometer)
I2: Alternate Intervention: Weight
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nRCT 4 weeks r I: Multicomponent (workplace)
-C/ED (1x FtF session 30 min
including EM setup & demonstration
& 3x Tel calls, weekly 7-10 min)








1) Stand Up every
≤30 min



























-C/ED (1xFtF session 30 min
including EM setup & demonstration
+ 4x Tel health coaching calls, 7-10
min, tapered: first 3M)
-Organisational support (1x
workshop generating strategies + 6x
workplace-delivered emails: first 3M)









sitting in ≥30 min
bouts. Target:
Gradually aiming















RCT 18 months r I: C/ED only (hospital)
-C/ED (14 FtF sessions [duration
unknown], tapered, covering PA, diet
& CPAP use - dietician &
physiotherapist delivered)







1) PA (MVPA) 2)
Diet
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PP 9 months r I: Environmental (workplace)






PA (stepping) None stated
Kallings et al.
(2009); Sweden





RCT 6 months r I: Multicomponent (primary care)
-C/ED (1x 30-min FtF session PAP &
Counselling, lecture, Tel follow-up -
health-professional delivered)
- Device self-monitoring (pedometer)
C: Usual care (+written materials















PP 12 months r I: Environmental (workplace)


















12 weeks r I1: Multicomponent (community)
- C/ED (12x FtF sessions, [duration
unknown], covering sedentary
behaviour & non-exercise activity.
Told not to exercise.)
- Device self-monitoring (pedometer)
I2-3:Alternate interventions:








and do not exercise
[I1].
PA (LPA, steps) Cardio-respiratory
fitness
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PP 3 months r I: C/ED only (workplace)
- C/ED (1 x 3 h FtF session initially,
1 x 1 h FtF session at 1 month)
- Structured exercise (unsupervised,




















c-nRCT 12 weeks r I: Multicomponent (workplace)
- C/ED (3x newsletters; handbook w/
goal setting & relapse prevention)
- Device self-monitoring & social
comparison (team pedometer
challenge each 2 weeks)
-Computer prompt (break hourly)
-EM (walking routes, maps, signage,
prompts)
C: Usual conditions (+newsletter)

















RCT 12 weeks r I: Multic mponent (community)
- C/ED (12x Tel calls, weekly, 15-
20min, behavioural counsellor)












x̅= 45.5 years (18+)




RCT 12 weeks r I: Environmental (workplace)
-EM (individual sit-stand
workstation)
-EM-ED (instructed to sit or stand as
desired and exercise as normal)
C: Usual conditions
No messaging: sit












RT 8 weeks r I: C/ED (workplace)
-C/ED (1x FtF session covering
strategies, 1x Tel follow-up, self-
monitoring)
Decrease sedentary
time by 30 min
workday with
breaks of 1-2 min
each half hour
(short breaks) or
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RCT 13 weeks r I: Environmental (workplace)
- Computer prompts only (interactive
computer software)




















RCT-x 2 weeks r I: Environmental (workplace)
-EM (shared treadmill desks)



















≥0.6 FT workers (office,
doing ≥70% work at
same desk)
RCT 3 months r I: Multicomponent (workplace)
-EM (individual sit-stand
workstation)
-EM-ED (demonstration by research
staff + instructional leaflet, self-
monitoring use by diary)
C: Usual conditions (+ brief












Stage 1-2 colorectal or
endometrial cancer
survivors completed




RCT 12 weeks r I: Multicomponent (community)
- C/ED (2x 2-hour Ftf group sessions
at wk 1 and 4, delivered by health
psychologists specialising in
behaviour change for device setup,
PA messaging, goal setting/planning,
self-monitoring, exercise coaching, 1
x 20-min Tel call at week 8)
- Device self-monitoring & Prompts
(Fitbit Alta)
C: Usual conditions (+ brief written
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desk ≥3 d/wk, sedentary
at work)
c-RCT 8 weeks r I: Multicomponent (workplace)
-C/ED (1x group FtF initial, 1 x
individual FtF (20 min)), weekly Tel
calls (5-10 min) by research staff)




computer software or app)
-Financial incentives (shopping
vouchers)
-EM (signage prompts about sitting
and PA, self-selected strategies:
moving equipment further,











x̅= 61.8 years (adults)
x̅= 24.8 kg/m2 (all)
Ethnicity not reported
Type 2 diabetes
RCT 12 weeks r I1: Multicomponent (hospital)
-C/ED (3x sessions, likely FtF,
[duration unknown]: advice by





-as per I1 but targeting locomotive PA
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3 months 3M I1 Multicomponent (community)
-C/ED (resource provision: 1x 25-















x̅= 45.8 years (20-65)
x̅= 32.9 kg/m2 (>30 or
WC > central obesity)
Ethnicity not reported
Inactive
RT 4 weeks r I1: C/ED (community)
- C/ED (1x FtF session [duration
unknown]: advice to sit less)












x̅= 37.4 years (28-53)
x̅= 24.5 kg/m2 (≤35)
Ethnicity not reported
Workers (sedentary at
work, with kids 3-8y)
c-RCT 6 months 6M I: C/ED (community)
C/ED (1x 30 min lecture + 1x FtF
session 30-60 min, 2x Tel calls,
behavioural counsellor delivered)
C: Usual conditions (+ delayed short
version of the C/ED)
Reduce and break
up sedentary time








FT workers (office, ≥ 6
h/d sedentary at work)
Inactive (<5 h/wk
MVPA)
RCT 4 weeks r I: Environmental (workplace)
-EM (individual underdesk stationary
cycle)
-EM-ED (FtF: Initial advice on cycle
use, self-monitoring + weekly
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RT 8 weeks r I1: Multicomponent (hospital)
- Device prompts (VTAP thigh-worn
monitor)
- Structured exercise (cardiac
rehabilitation) (2x FtF on-site 1-hour
aerobic and strength exercise
sessions, physiotherapist delivered).
- C/ED (no sedentary component, but
optional nutrition counseling,
smoking cessation, diabetes and
stress management, and psychosocial
support)
I2: Alternate intervention (cardiac
























c-RCT 19 weeks 10 weeks I: Multicomponent (workplace)
- C/ED (website-delivered education
+6 x emails, tapered)
- Social support (blog)













90F,  0M (female)
x̅=55.3 years (18-75)
x̅=31.0 kg/m2 (≥ 25)
Ethnicity not reported
Breast cancer
RCT 6 months r I: Multicomponent (community)
- C/ED (16x 30 min Tel calls,
tapered, delivered by dieticians
trained in behavioural counselling)


















RCT 6 months r I: Environmental modification
(workplace)
EM (sit-stand workstation, with anti-
fatigue mat, installed or checked by
ergonomics staff)
ED-EM (self-monitoring desk use
and energy output, instruction on
desk use)
Reduce sitting by
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PP 8 weeks r I: C/ED (community)
- C/ED only (5x Tel calls, 20-30 min,
tapered delivered by 'health coach')
1) Reduce sitting
time by 2 h/day via
standing & moving












20%  C/W, 76% African
American, 5% 'Other'
Workers (desk, office)
RCT 3 months r I: Multicomponent (workplace)
-EM (shared treadmill desks)
-EM-ED (instruction on amout of use,

















97%  C/W, 3% African
American
Sedentary
RT 6 months r I1: Multicomponent (domestic)
-C/ED (3x monthly Ftf sessions, 3 x
monthly Tel calls, newsletters)
-Device self-monitoring (pedometer)
I2: Alternate intervention (Walking)
-C/ED (3x monthly Ftf sessions, 3 x







90 min of TV
≥5x/week








 x̅=43.4 years (≥18)
x̅=30.3 kg/m2 (all)
35% African American /
33% Non-Hispanic





6 months r I1: Structured 'exercise' class
(workplace)
-Structured 'exercise' at work (1x 15
min session/day, peer led)
I2: Environmental (workplace)
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RCT 16 weeks r I1: Multicomponent (hospital)
-C/ED (3x FtF sessions, 29-102 min,
delivered by nurses trained in
behavioural counselling)
- SMS prompts & goal reminders















x̅= 59.6 years (adults)




RCT 16 weeks r I: Multicomponent (hospital)
- C/ED (3x FtF sessions, 60-90 min,
delivered by nurse/occupational
therapist trained in behavioural
counselling)
- SMS prompts & goal reminders
(tailored, self-selected dose)
C: Usual care





4) All sitting bouts
≤ 30 min
Standing Sitting time (all)




x̅= 32.8 years (≥18)





9 months r I1: Multicomponent (community)
-C/ED (3x Tel calls, 30 min, dietitian
delivered)
-Device self-monitoring (pedometer
& CALORIEKING site/app for diet)
-Online support (behaviour therapy
website for diet/PA & social support
via discussion board)
I2: Alternate intervention
-C/ED (child behaviour: separate
study)
C: Usual care (separate study)
Reduce sitting time
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c-RCT 6 months r Multicomponent (workplace)
- C/ED (5x 20-30 min FtF
counselling sessions, Occupational
physician-delivered- choice of PA,
diet or sedentary behaviour)
-Device self-monitoring (pedometer)
- EM (workplace audit / employer-
negotiated change)
C: Usual conditions (occupational























90% 'native' to study
country
RCT 12 weeks 9M I: Multicomponent (community)
- C/ED/Structured exercise: 12x 90
min structured exercise session using
behaviour change techniques,
delivered by football coaches
- Device self-monitoring, social
comparison, reminders: (SitFIT
device + social media support + game-
based app)










x̅= 33.2 years (20-56)








r I: Multicomponent (primary care)
- C/ED (12x 'Line' and email
contacts, weekly, with health
professional advice, information and
reminders + website information)
- Device self-monitoring, social
comparison, reminders (sensor +
smartphone app + website)
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x̅= 39.1 years (18-65)
x̅= 25.8 kg/m2 (all)
75% C/W
FT workers





- C/ED (4 months: worksite staff-
delivered emails, promotional flyers,
e-newsletters)
-EM (18 months: individual sit-stand
workstation + shared treadmill desks)
C: Usual conditions (+ e-newsletters
on energy, ergonomics and












Footnotes: ME = maintenance evaluation; F = female; M = male; I = intervention; C = control; FT=full-time; PA = Physical activity; LPA = light PA; MVPA
= moderate-vigorous PA; MPA = moderate PA; VPA = vigorous PA; C/W = Caucasian/White as reported by study (Caucasian, White, British White, non-
Hispanic White) ; ?= Data unreported.
*Study designs: c- = cluster, n = non, R = randomised, C = controlled, T = Trial, -x = crossover, PP = pre-post study (single arm).
**Intervention components: C/ED = counselling/education; EM = environmental modification; FtF = face-to-face; Tel = Telephone SMS = short message
system.
***Criteria only required if other criteria are not met. Must be: overweight and at risk for type 2 diabetes and/or obese BMI (≥27.5 for South Asians otherwise
≥30 kg/m2) (Biddle); inactive and/or BMI >=25 (Eakin); insufficiently inactive and/or >=overweight WC and/or not meeting diet recommendations (Verweij);
above the threshold for BMI or one of the other 5 cardiometabolic biomarker risk factors (Yang).
Resendiz et al. (2019) average age is median
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Supplementary Table S4 Baseline anthropometric characteristics (mean ± SD) and effects on sedentary behaviour in controlled trials of 34 adult sedentary behaviour 
interventions ≥7 days
SB 





min/day kg kg/m2 cm % kg kg mmHg mmHg
Aadahl et al. (2014) -19.2 80.4 ± 16.3 27.3 ± 5.0 93.8 ± 13.5 32.5 ± 9.3     
Alkhajah et al. (2012) -78.0 62.2 ± 9.4 22.1 ± 2.6 81.8 ± 8.8 29.2 ± 4.6 18.4 ± 4.5 44.1 ± 6.2   
Ashe et al. (2015) -21.1 77.9 ± 19.2 29.3 ± 6.8     133 ± 15 82 ± 8
Balducci et al. (2019) -48.0 b 84.1 ± 16.5 30.1 ± 5.1 103.6 ± 12.8 31.7 ± 10.2  56.5 ± 11.4 140 ± 20 83 ± 12
Biddle et al. (2015) -7.2 98.6 ± 18.8 34.6 ± 5.1 103.3 ± 14.2 40.6 ± 7.1   120 ± 15 84 ± 10
Butler (2018)  70.6 ± 14.3 23.0 ± 3.0 74.4 ± 6.9      
Carr et al. (2013) -18.2 89.4 ± 15.0 32.4 ± 4.7 92.7 ± 11.2    119 ± 13 76 ± 10
Danquah et al. (2017) -27.0  26.0 ± 4.9 91.6 ± 13.0 30.2 ± 7.6 23.9 ± 11.1 53.4 ± 11.1   
Dunning et al. (2018) -24.0 69.6 ± 9.9 23.8 ± 2.8  24.5 ± 7.9   109 ± 8 74 ± 8
Garland et al. (2018) -41.1  24.8 ± 4.9       
Graves et al. (2015) -51.6 68.8 ± 15.0 24.8 ± 4.5     119 ± 13 73 ± 9
Healy et al. (2013) -82.6 80.2 ± 17.1 26.8 ± 5.4 91.2 ± 13.6 29.4 ± 10.0 24.2 ± 11.3 56.1 ± 11.3 131 ± 14 78 ± 8
Healy et al. (2017) -36.3 80.2 ± 19.7 28.6 ± 6.1 93.6 ± 14.9 33.1 ± 9.5 27.0 ± 13.0 51.7 ± 11.1 127 ± 15 78 ± 11
Kallings et al. (2009) -60.0 88.2 ± 12.6 30.1 ± 3.1 105.8 ± 8.5 36.7 ± 7.2 32.3 ± 7.5  140 ± 2 81 ± 1
Kozey-Keadle et al. (2014) -88.3 99.4 ± 14.8 35.0 ± 4.7  45.5 ± 5.8   130 ± 10 79 ± 9
Lin et al. (2017) -0.9 64.8 ± 12.1 24.0 ± 3.2 82.8 ± 9.4    118 ± 14 79 ± 10
Lyons et al. (2017) -27.0 82.4 ± 10.9 30.3 ± 3.5  45.1 ± 5.3     
MacEwen et al. (2017) -97.4 99.6 ± 24.6 35.8 ± 8.3 111.4 ± 13.6 42.7 ± 8.3   129 ± 12 86 ± 8
Mainsbridge et al. (2014)        135 ± 17 85 ± 14
Malaeb et al. (2019)  78.5 ± ? 28.4 ± ?  38.5 ± ? 28.5 ± ? 45.5 ± ?   
Mantzari et al. (2018) -59.9 74.5 ± 14.7 25.1 ± 4.8 87.7 ± 13.5 26.8 ± 10.4   128 ± 13 78 ± 9
Maxwell-Smith et al. (2018) 8.6  28.3 ± 5.0     142 ± 18 86 ± 12
Maylor et al. (2018) -1.0 76.4 ± 7.6 25.9 ± 0.5 86.5 ± 2.8 28.8 ± 1.4   126 ± 7 78 ± 5
Miyamoto et al. (2017) -77.8 66.6 ± 3.9 24.6 ± 1.1       
Pesola et al. (2017) 11.3 71.9 ± 14.8 24.5 ± 3.8  27.8 ± 8.1   117 ± 11 74 ± 8
Peterman et al. (2019) -12.1 79.0 ± 17.0 28.3 ± 6.7   28.5 ± 13.0 47.8 ± 8.1 112 ± 10 69 ± 8
Puig-Ribera et al. (2015) -16.3  25.7 ± 4.4 87.9 ± ?    121 ± 17 78 ± 11
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Resendiz et al. (2019) -95.7  32.2 ± 5.2 96.8 ± 12.2      
Schuna et al. (2014) -21.6 97.0 ± 24.5 35.9 ± 8.5  45.0 ± 5.6     
Taylor et al. (2016) – 
Booster breaks -85.7 87.3 ± 15.1 31.2 ± 3.0 100.8 ± 8.3    117 ± 19 70 ± 8
Taylor et al. (2016) – 
Computer breaks -87.7 78.6 ± 12.2 29.0 ± 2.6 96.5 ± 6.8    117 ± 17 70 ± 8
Thomsen et al. (2016) -27.6 78.4 ± 17.3 25.5 ± 6.5 86.7 ± 18.5    128 ± 21 78 ± 11
Thomsen et al. (2017) -132 75.2 ± 17.2 26.4 ± 5.4 92.1 ± 14.1    131 ± 20 78 ± 10
Zhu et al. (2018) 8.0 74.4 ± 18.1 25.8 ± 4.9     119 ± 15 76 ± 10
BMI = Body Mass Index; SB = Sedentary Behaviour; BP = Blood Pressure
a Effectiveness of intervention (net of control) in min / day on overall sedentary behaviour (SB) measured by self-report or device. When unreported, overall effects were 
loosely extrapolated from domain-specific effects (e.g., weekday and weekend reported separately) and exposure to the domain (e.g., 5 weekdays versus 2 weekend 
days/week). When only partial information was reported (e.g., workhours only) the extrapolation was based on the assumption of no effect outside of the reported domains. 
Percentages were converted to hours per day based on reported total amounts of time otherwise 8 hours working and 16 hours awake.
a  For interim results reported in Balducci 2017, the corresponding value for effectiveness of intervention on sedentary behaviour is -33.0 min / day
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Supplementary Table S5 Study baseline levels of blood biomarkers (mean ± SD) in controlled trials of 34 adult sedentary behaviour interventions ≥7 days
TC HDL LDL TG Glucose Insulin HbA1c
Study
 
mM mM mM mM mM pmol/L %
Aadahl et al. (2014) 5.3 ± 1.0 1.5 ± 1.5 3.2 ± 3 1.2 ± 1.1 5.6 ± 1.0 52.1 ± 45 5.6 ± 0.5
Alkhajah et al. (2012) 4.5 ± 0.9 1.5 ± 0.4 2.7 ± 0.7 0.9 ± 0.8 4.9 ± 0.4   
Ashe et al. (2015)        
Balducci et al. (2019) 4.7 ± 1.0 1.2 ± 0.4 2.9 ± 0.9 1.5 ± 0.9 a 7.6 ± 2.7 77.4 ± 74.7 a 7.4 ± 1.5
Biddle et al. (2015) 4.9 ± 1.0 1.3 ± 0.3 3.0 ± 0.7 1.5 ± 1.2 4.8 ± 0.6 86 ± 56.5 5.6 ± 0.3
Butler (2018)       5.4 ± 2.5
Carr et al. (2013) 4.9 ± 0.7 1.2 ± 0.5 3.0 ± 0.7 1.3 ± 0.6    
Danquah et al. (2017)        
Dunning (2018) 4.8 ± 0.8 1.6 ± 0.3 2.8 ± 0.7 1.0 ± 0.5 4.7 ± 0.4 37.1 ± 15.2  
Garland (2018)        
Graves et al. (2015) 4.2 ± 0.9   1.6 ± 0.7 5.1 ± 0.7   
Healy et al. (2013) 5 ± 0.9 1.5 ± 0.4 2.9 ± 0.8 1.1 ± 0.5 4.8 ± 0.9 52.7 ± 28.9  
Healy et al. (2017) 5.4 ± 1.0 1.5 ± 0.4 3.2 ± 0.9 1.4 ± 0.7 5.1 ± 1.4 61.4 ± 112  
Kallings et al. (2009) 5.5 ± 0.1 1.7 ± 0.1 3.3 ± 0.1 1.3 ± 0.1 5.4 ± 0.1  4.9 ± 0.1
Kozey-Keadle et al. (2014) 4.7 ± 0.8 1.7 ± 0.5  1.9 ± 1.2 5.8 ± 0.7 133 ± 86.6  
Lin et al. (2017) 5 ± 0.9 1.5 ± 0.4 2.8 ± 0.7 1.3 ± 0.7 4.8 ± 0.7 42.6 ± 31.2  
Lyons et al. (2017)        
MacEwen et al. (2017) 5.1 ± 0.9 1.5 ± 0.4 2.9 ± 0.7 1.6 ± 0.8 5.8 ± 0.5  6.9 ± 0.5
Mainsbridge et al. (2014 )        
Malaeb et al. (2019)        
Mantzari et al. (2018) 4.8 ± 1.0 1.4 ± 0.3 2.7 ± 1.0 1.4 ± 0.6   5.2 ± 2.4
Maxwell-Smith et al. (2018)        
Maylor et al. (2018) 4.4 ± 0.4 1.4 ± 0.2      
Miyamoto et al. (2017) 5.3 ± 0.2  3.3 ± 0.2 1.2 ± 0.1 7.0 ± 0.4  7.0 ± 0.2
Pesola et al. (2017) 4.8 ± 0.8 1.8 ± 0.5 2.6 ± 0.9 1.0 ± 0.9 5.3 ± 0.5 38.2 ± 25.6  
Peterman et al. (2019) 4 ± 0.8 1.1 ± 0.2 2.5 ± 0.7 1.2 ± 0.6 4.1 ± 0.6   
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Puig-Ribera et al. (2015)        
Resendiz et al. (2019)        
Schuna et al. (2014)        
Taylor et al. (2016) - Booster breaks 5.0 ± 0.4 1.4 ± 0.2 2.9 ± 0.3 1.4 ± 0.5 5.4 ± 2.1   
Taylor et al. (2016) - Computer breaks 4.8 ± 0.3 1.3 ± 0.2 2.8 ± 0.3 1.3 ± 0.3 5.3 ± 1.3   
Thomsen et al. (2016) 5.5 ± 1.3 1.5 ± 0.4 3.1 ± 1.1 1.4 ± 0.7   5.2 ± 0.1
Thomsen et al. (2017) 5.2 ± 1.1 1.6 ± 0.5 3.1 ± 0.9 1.2 ± 0.6   5.5 ± 0.8
Zhu et al. (2018) 4.7 ± 0.7 1.6 ± 0.5 2.9 ± 0.7 1.1 ± 0.6 5.4 ± 0.7 73.6 ± 41.4  
TC = Total Cholesterol; HDL = High-density lipoprotein cholesterol; LDL = Low-density lipoprotein cholesterol; TG = triglycerides
a Different value reported in relation to the interim outcomes in Balducci 2017: 1.8 ± 1.4 mM triglycerides and 89.5 ± 86.4 pM insulin.
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Supplementary Table S6 Individual study risk of bias assessment for 1) anthropometric and blood pressure, 2) 

























Measure 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
1 Aadahl 2014 + + + + + + ? ? ? + + + + + + ? ? ?
2 Alkhajah 2012 - - - + + + ? - - + + + + + + - - -
3 Ashe 2015 ?   ?   ?   +   +   ?   
4 Balducci, 2019* + + + + + + + + + + + + - - + - - +
5 Biddle 2015 + + + + + + ? ? ? + + + + + + ? ? ?
6 Butler 2018 ? ? ? - - - + + + ? + + + + ? - - -
7 Carr 2013 +  + +  + ?  ? +  + ?  + ?  ?
8 Danquah 2017 +   +   +   +   +   +   
9 Dunning, 2018 + + + ? ? ? + + + ? ? ? + + + ? ? ?
10 Garland, 2018 -   +   -   -   +   -   
11 Graves 2015 + + + + + + + + + + + + ? ? ? ? ? ?
12 Healy 2013 - - - + + + + + + + + + + + + - - -
13 Healy 2017 + + + + + + ? ? ? + + + + + + ? ? ?
14 Kallings 2009 ? ? ? + + + + + + + + + + + + ? ? ?
15 Kozey Keadle 2014 - - - - - - ? ? ? + + + + + + - - -
16 Lin 2017 ? ? ? + + + ? ? ? + + + + + + ? ? ?
17 Lyons 2017 +   +   +   +   +   +   
18 MacEwen 2017 + + + - - - ? ? ? + + + + + + - - -
19 Mainsbridge 2014 ?   +   +   ?   ?   ?   
20 Malaeb, 2019 -   -   -   ?   -   -   
21 Mantzari, 2018 ? ? ? ? ? ? + + + + + + + + + ? ? ?
22 Maxwell-Smith 2019 ?   +   +   +   +   ?   
23 Maylor, 2018 +  + ?  ? +  + ?  ? +  + ?  ?
24 Miyamoto 2017 + + + + + + + + + + + + + + + + + +
25 Pesola 2017 + + + + + + + + + + + + + + + + + +
26 Peterman, 2019 ? ? ? + + + - - - ? + + - - - - - -
27 Puig-Ribera 2015 ?   +   ?   +   +   ?   
28 Resendiz, 2019 ?   ?   +   ?   +   ?   
29 Schuna 2014 ?   +   +   +   +   ?   
30 Taylor 2016 ? ? ? ? ? ? ? ? ? ? ? ? + + + ? ? ?
31 Thomsen 2016 + + + + + + + + + + + + + + + + + +
32 Thomsen 2017 + + + + + + + + + + + + + + + + + +
33 Zhu, 2018 - - - + + + - - - ? + + + + + - - -
Total Low Risk (+) 15 11 13 23 15 16 18 11 12 23 19 20 27 18 20 6 4 5
Total Unclear risk (?) 12 6 6 6 3 4 11 7 8 9 2 3 3 1 2 17 9 11
Total High risk (-) 6 4 4 4 3 3 4 3 3 1 0 0 3 2 1 10 8 7
Total All 33 21 23 33 21 23 33 21 23 33 21 23 33 21 23 33 21 23
Notes: 1=anthropometry & blood pressure outcomes; 2=glucose metabolism outcomes; 3=lipid metabolism outcomes; 
+ = low risk of bias; ? = unclear risk of bias (some concerns); – = high risk of bias.
* Data were extracted from the earlier paper related to this study (Balducci 2017) when it was not reported in the 2019 
paper (%BF; FFM; BMI; fasting insulin; HOMA). Risk of bias for Balducci 2017 was low for all criteria. 
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Supplemental Table S7 Assumption tests regarding publication bias
Outcome Begg’s test
Weight, kg z = -0.21, p = 0.870
Body Mass Index, kg/m2 z = -0.57, p = 0.602
Waist circumference, cm z = 1.40, p = 0.162
Body fat, % of body weight z = 0.68, p = 0.499
Fat mass, kg z = 1.13, p = 0.260
Fat-free mass, kg z = -1.20, p = 0.368
Systolic BP, mmHg z = -0.49, p = 0.657
Diastolic BP, mmHg z = -1.38, p = 0.183
Glucose, mM z = 0.70, p = 0.484
Insulin, pM z = 0.36, p = 0.721
HbA1c, % z = -0.52, p = 0.754
Total cholesterol, mM z = -0.71, p = 0.509
HDL cholesterol, mM z = 0.08, p = 0.932
LDL cholesterol, mM z = -0.68, p = 0.538
Triglycerides, mM z = 1.35, p = 0.177
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Table S8: Meta-regression: associations of study characteristics with intervention effects on cardiometabolic biomarkers displaying low heterogeneity
 Unadjusted Age adjusted
 k, N b (95% CI) p I2, p n, N b (95% CI) p I2, p
Weight (kg) 25, 1839   23.6%, p=0.142 25, 1839   23.6%, p=0.142
Mean baseline age, per 10 y 25, 1839 -0.51 (-0.84, -0.18) 0.002 0.0%, p = 0.504  - - -
Mean baseline BMI, kg/m2 25, 1839 -0.02 (-0.15, 0.10) 0.731 26.6%, p = 0.115 25, 1839 0.03 (-0.07, 0.12) 0.579 0.0%, p = 0.462
Mean baseline level 25, 1839 0.00 (-0.04, 0.05) 0.873 26.8%, p = 0.113 25, 1839 0.02 (-0.01, 0.05) 0.313 0.0%, p = 0.505
Sedentary effectiveness, h/day 25, 1839 -0.17 (-0.84, 0.50) 0.625 26.6%, p = 0.115 25, 1839 -0.14 (-0.61, 0.33) 0.565 0.0%, p = 0.463
Duration (vs ≤3 months) 25, 1839  0.036 28.0%, p = 0.106 25, 1839  0.009 2.4%, p = 0.428
3–6 months  -1.26 (-2.25, -0.27) 0.012  -0.60 (-1.47, 0.26) 0.173  
>6 months  -0.00 (-1.15, 1.15) 0.997   0.25 (-0.66, 1.15) 0.591  
Risk of bias (vs High risk) 25, 1839  0.640 29.1%, p = 0.096 25, 1839  0.020 5.6%, p = 0.385
Some concerns  -0.47 (-1.85, 0.91) 0.507   0.67 (-0.69, 2.03) 0.335  
Low risk  -0.43 (-1.37, 0.51) 0.366   0.17 (-0.66, 1.00) 0.692  
Body fat percentage, % 16, 1618 5.5%, p=0.390 16, 1618 5.5%, p=0.390
Mean baseline age, per 10 y 16, 1618 -0.13 (-0.38, 0.13) 0.325 6.5%, p = 0.380  - - -
Mean baseline BMI, kg/m2 16, 1618 -0.04 (-0.13, 0.05) 0.397 8.5%, p = 0.358 16, 1618 -0.02 (-0.14, 0.10) 0.732 13.0%, p = 0.311
Mean baseline level 16, 1618 -0.04 (-0.10, 0.01) 0.130 0.0%, p = 0.482 16, 1618 -0.04 (-0.11, 0.03) 0.238 3.9%, p = 0.408
Sedentary effectiveness, h/day 16, 1618 -0.21 (-0.75, 0.34) 0.456 8.9%, p = 0.354 16, 1618 -0.31 (-0.88, 0.25) 0.274 5.8%, p = 0.388
Duration (vs ≤3 months) 16, 1618 0.194 16.2%, p = 0.276 16, 1618 0.257 12.1%, p = 0.323
3–6 months  -0.56 (-1.19, 0.06) 0.078   -0.48 (-1.11, 0.16) 0.143  
>6 months  -0.06 (-0.77, 0.66) 0.880   0.11 (-0.67, 0.89) 0.786  
Risk of bias (vs High risk) 16, 1618 0.209 16.3%, p = 0.276 16, 1618 0.332 17.5%, p = 0.267
Some concerns  -0.76 (-1.61, 0.09) 0.081   -0.68 (-1.57, 0.21) 0.132  
Low risk  -0.51 (-1.38, 0.35) 0.243   -0.44 (-1.34, 0.45) 0.331  
Fat mass, kg 6, 724 26.6%, p=0.235 6, 724 26.6%, p=0.235
Mean baseline age, per 10 y 6, 724 -0.22 (-0.64, 0.19) 0.296 26.7%, p = 0.243  - - -
Mean baseline BMI, kg/m2 6, 724 -0.12 (-0.30, 0.06) 0.179 17.1%, p = 0.306 6, 724 -0.10 (-0.34, 0.14) 0.416 35.4%, p = 0.200
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Mean baseline level 6, 724 -0.08 (-0.18, 0.01) 0.082 0.0%, p = 0.436 6, 724 -0.09 (-0.22, 0.05) 0.212 20.6%, p = 0.286
Sedentary effectiveness, h/day 6, 724 -0.67 (-1.71, 0.36) 0.202 22.8%, p = 0.269 6, 724 -0.78 (-1.72, 0.16) 0.104 0.0%, p = 0.422
Duration (vs ≤3 months) 6, 724 0.506 55.6%, p = 0.080 6, 724 0.685 63.1%, p = 0.067
3–6 months  -0.83 (-2.24, 0.58) 0.247   -1.61 (-5.37, 2.16) 0.403  
>6 months  -0.06 (-1.45, 1.33) 0.930   -0.20 (-1.74, 1.35) 0.804  
Risk of bias (vs High risk) 6, 724 0.637 50.3%, p = 0.110 6, 724 0.837 63.1%, p = 0.066
Some concerns  -0.30 (-1.48, 0.89) 0.624   -0.22 (-1.75, 1.31) 0.778  
Low risk  -0.56 (-1.73, 0.60) 0.344   -0.37 (-2.37, 1.63) 0.716  
Systolic Blood Pressure, 
mmHg 25, 1932 8.6%, p=0.341 25, 1932 8.6%, p=0.341
Mean baseline age, per 10 y 25, 1932 0.38 (-0.49, 1.24) 0.392 8.1%, p = 0.349  - - -
Mean baseline BMI, kg/m2 24, 1903 0.02 (-0.29, 0.34) 0.882 15.1%, p = 0.256 24, 1903 -0.02 (-0.35, 0.32) 0.922 15.7%, p = 0.251
Mean baseline level 24, 1911 0.04 (-0.11, 0.18) 0.617 4.3%, p = 0.402 24, 1911 0.12 (-0.11, 0.36) 0.303 4.8%, p = 0.396
Sedentary effectiveness, h/day 23, 1882 -0.48 (-2.16, 1.20) 0.573 7.9%, p = 0.355 23, 1882 -0.71 (-2.64, 1.22) 0.472 11.3%, p = 0.312
Duration (vs ≤3 months) 25, 1932 0.708 14.7%, p = 0.261 25, 1932 0.743 14.0%, p = 0.273
3–6 months  0.31 (-2.49, 3.10) 0.828   0.16 (-2.67, 2.99) 0.912  
>6 months  -1.09 (-4.01, 1.84) 0.466   -1.19 (-4.13, 1.76) 0.430  
Risk of bias (vs High risk) 25, 1932 0.375 10.8%, p = 0.313 25, 1932 0.607 12.9%, p = 0.288
Some concerns  1.54 (-1.57, 4.65) 0.332   1.40 (-2.10, 4.90) 0.433  
Low risk  1.80 (-0.76, 4.36) 0.168   1.66 (-1.21, 4.53) 0.258  
HDL Cholesterol, mM 22, 1760 22.5%, p=0.168 22, 1760 22.5%, p=0.168
Mean baseline age, per 10 y 22, 1760 -0.01 (-0.03, 0.00) 0.011 0.7%, p = 0.450  - - -
Mean baseline BMI, kg/m2 22, 1760 0.00 (-0.01, 0.00) 0.304 14.3%, p = 0.273 22, 1760 -0.00 (-0.01, 0.01) 0.768 5.2%, p = 0.392
Mean baseline level 21, 1739 -0.08 (-0.23, 0.08) 0.344 6.3%, p = 0.378 21, 1739 -0.06 (-0.22, 0.09) 0.428 7.4%, p = 0.365
Sedentary effectiveness, h/day 21, 1739 -0.02 (-0.06, 0.01) 0.222 3.3%, p = 0.416 21, 1739 -0.04 (-0.08, 0.00) 0.046 0.0%, p = 0.583
Duration (vs ≤3 months) 22, 1760 0.266 27.6%, p = 0.124 22, 1760 0.163 10.6%, p = 0.325
3–6 months  -0.05 (-0.12, 0.01) 0.104   -0.04 (-0.10, 0.02) 0.175
>6 months  -0.02 (-0.08, 0.05) 0.604   -0.01 (-0.07, 0.05) 0.735  
Risk of bias (vs High risk) 22, 1760 0.023 9.6%, p = 0.335 22, 1760 0.035 5.2%, p = 0.392
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3
Some concerns  -0.06 (-0.12, 0.00) 0.035   -0.09 (-0.18, 0.01) 0.076  
Low risk  -0.06 (-0.10, -0.01) 0.015   -0.07 (-0.14, 0.00) 0.043
Table presents unstandardized regression coefficient (b) and 95% confidence interval (CI) and p value from meta-regression of controlled trials of adult sedentary behaviour 
interventions ≥7 days. Italics indicates overall p value (omnibus test). No meta-regression performed for BMI or LDL cholesterol, since I2=0.
a k = total number of interventions included and n = total number of individuals analysed in the included interventions, in the meta-regressions or main metaanalysis 
(boldface) b Residual heterogeneity (I2 and p from Cochrane’s Q test) with overall heterogeneity in the main metaanalysis shown in boldface 
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